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ABSTRACT 
 
G-protein-coupled receptors (GPCRs) represent, nowadays, one of the most productive 
source of drug targets. Some GPCRs members are, however, poorly studied and hence 
cannot be targeted for therapies yet. Among these, there are more than 90 GPCRs still 
orphan, i.e. with no described endogenous ligand and no clearly defined function. The 
orphan receptors CELSR2 and Frizzled4 (Fz4), have recently drawn the attention of 
the scientific community in virtue of their involvement in cancer progression. CELSR2 
is an adhesion GPCR (class B GPCRs) overexpressed in glioblastoma. Until now, 
CELSR2 endogenous ligands have not yet been identified. Fz4 belongs to class F 
GPCRs and it is activated by the lipoproteins WNTs and Norrin. Misregulation of Fz4 
activity is involved in tumor proliferation and cancer stem cell genesis in many types 
of malignancies, such as glioblastoma, colorectal and breast cancer. To date, the 
existence of low-molecular-weight organic molecules binding to and modulating Fz4 
has not been reported. Thus, the identification of ligands/modulators of CELSR2 and 
Fz4 activity could pave the way for new therapeutic strategies to treat cancer. In this 
thesis, I attempted to identify CELSR2 and Fz4 ligands by using the “Pharmacological 
chaperone readout”, an innovative screening platform (PC-platform) that identifies 
ligands in virtue of their potency in affecting the tridimensional structure and the 
intracellular localization of a protein target. 
The first chapter of the thesis describes the results obtained in the attempt of 
identifying new ligands of Fz4 receptor. To achieve this aim, a cell line expressing a 
Fz4 mutant, Fz4-L501fsX533, was generated. This frameshift mutation is responsible 
in vivo for the occurrence of the Familial Exudative Vitreoretinopathy (FEVR), a 
pathology of the retina. The resulting mutant, here referred to as Fz4-FEVR, 
aggregates intracellularly in the Endoplasmic Reticulum (ER) without reaching the 
Plasma Membrane (PM) of the cell where, in contrast, the wt receptor localizes at 
steady state. To identify Fz4 wt modulators, a library of organic molecules has been 
screened for pharmacological chaperones of Fz4-FEVR, i.e. for molecules able to 
rescue the folding and correct localization of Fz4-FEVR at PM. Using such read-out, 
the organic molecule FzM1 has been thus identified as Fz4-FEVR pharmacological 
chaperone. The pharmacological chaperone FzM1 acts as allosteric inhibitor of the 
Fz4-wt receptor, binding directly to the wt receptor and inhibiting the signalling 
pathway Fz4 is involved in. I also performed a structure-activity relationship (SAR) 
analysis using FzM1 as lead to identify the first allosteric agonist of Fz4, FzM1.8.  
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As discussed in the second chapter of this thesis, a specific PC-platform was 
developed for the identification of ligands of CELSR2. To achieve this aim, a 
misfolded version of CELSR2 was generated and then a library of metabolites was 
screened looking for compounds binding to the receptor and correcting its folding. 
Zebrafish eggs were used as biomass to obtain a library of metabolites which were 
screened for pharmacological chaperone efficiency. The outcome of the screening 
identified three compounds acting as modulators of CELSR2: cholesterol, PGE2 and 
β-carotene. They do not target the orthosteric binding site of CELSR2 but they are 
located in an hydrophobic region of the receptor at the interface between the TM-
bundle and the lipid bilayer. The potential ability of these molecules to allosterically 
modulate CELSR2 function could have important implications both in physiological 
and pathological cell conditions. 
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Chapter 1 
INTRODUCTION 
Folding is a physical process by which proteins reach their functional 
three dimensional structure 
 
Proteins are pivotal units for cell function and vitality. To be properly active, a protein 
must “properly fold”, i.e. attain its correct three-dimensional structure. Final and 
correct “native-conformations” are achieved when unfolded nascent chains, emerging 
from the ribosomes, undergo a series of conformational changes and structural 
transitions that characterize their specific folding pathways
1
.  
The free energy endowed by a nascent chain is very high
2
. At the beginning of the 
folding process, entropy forces the unfolded chain to assume and switch among all the 
allowed structural conformations
2
. Later, during the folding process, the enthalpy 
generated by the interactions established between different amino acids and domains 
of the protein counterbalances the entropic disorder and stabilize protein native states, 
reducing total Free Energy to an absolute minimum
3
.  
The native and the unfolded states have only a minimal difference of free energy (only 
5-10 kcal/mole)
4
. However, only in the native conformation a protein can exert the 
specific function to which it has been destined
2
. This is because only in this state the 
amino acids contributing to the proteins’ active sites are correctly located in the space 
and relatively to each others. 
During the folding process, proteins may assume the so called intermediate 
conformations
5
. Compared with the native state, these conformations are less stable, 
have already acquired secondary structures but miss the correct final tertiary structure. 
One of the partially folded, intermediate states is named the “molten globule”4. 
In vivo, most of the proteins achieve the native state in a time range from milliseconds 
to seconds 
6
. Longer time is required, in contrast, for those proteins characterized by a 
complex structure (transmembrane and multi-span proteins)
7
. 
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Proteins fold moving in an energy landscape 
 
The energy landscape perspective is the most recent theory explaining the folding 
process of a protein
8,9
. It describes the free energy endowed by the polypeptide chain 
as a funnel-like landscape with many local minima corresponding to small energy 
traps (metastable states) and a single global minimum corresponding to the native 
state
10
. In the energy funnel, the formation of conformations with lower free energy 
occurs more likely than those with higher free energy and thus, the unfolded protein 
irreversibly moves towards the minimal free energy of the native conformation
11
. 
In the simplest case, the folding process involves only two states: the native state (N) 
and the unfolded state (U). 
U ↔ N 
In this case the folding process is represented by a smooth energy landscape and the 
folding and unfolding processes have the same running time (Fig. 1).  
 
 
 
 
 
Figure 1. Energy landscape in which each point represents a 
protein conformation. The vertical axis represents the free energy 
(N stands for native state). (Adapted from Dill and Chan, 1997).  
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In most of cases, proteins take more time to roll down a rough funnel characterized by 
many small hills and valleys
12
 (Fig. 2). 
 
 
 
 
In these cases, the folding process alternates slow and fast phases. The slow phase 
depends on the presence of local minima in which partially folded intermediates can 
be trapped. The energy barrier that an intermediate has to overcome to achieve the 
native state is very high. For this reason, the intermediate state (I) is considered a 
competitor of the native state
12
.  
U ↔I ↔ N 
  
Figure 2. Energy landscape showing 
energetic hills and traps which hamper the 
protein folding progress (adapted from 
Dill and Chan, 1997).  
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Protein Folding is a multistep process 
 
How a protein reaches its three-dimensional conformation constitutes a central 
problem in biology. Anfinsen’s pioneristic experiments on the in vitro refolding of the 
protein Ribonuclease I
13
, suggested that all the information required for a protein to 
fold are contained in its primary sequence. Although these refolding experiments could 
be repeated with other small, single domain proteins, large multi-domain proteins 
normally tend to aggregate when they are refolded in vitro
14
. This reflects what 
happens in a cell, where most of the proteins requires cellular assistance to fold 
properly and efficiently
15
.  
Protein folding is a multistep process: 
•  The first step includes the formation of secondary structures (α-helix and β-sheets) 
which fold rapidly because they are stabilized by intramolecular hydrogen bonds
16,17
. 
•  In a second phase of the folding process hydrophobic interactions, protein-solvent 
interactions and eventually disulfide bridges are established so that the hydrophilic and 
hydrophobic side chains can face to aqueous solvent and hydrophobic core of the 
protein, respectively
18
. 
• Finally, coarse movements of the different protein sub-domains lead to the 
acquisition of the final native conformation. 
Despite enthalpy would push a folded protein toward an unfolded and chaotic 
organization of the amino-acidic chain, the native conformation is an irreversible state 
for a protein (at least for those kept at physiological condition of temperature, pH and 
ionic strength)
19
. Intra-chain interactions, hydrogen bonds, hydrophobic interactions, 
and disulfide bridges as well as interactions established between side chains and the 
solvent all help stabilizing the native conformation of the protein and contribute to 
protein stability
20
. 
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Chaperones assist protein folding 
 
Although all information to reach the native, biologically active state of a protein is 
present in the amino acid sequence
21
, cells invest in a complex network of molecular 
chaperones which will assist the nascent chain and make the folding process more 
efficient
15
. Chaperones are nanoscale molecular machines that recognize incompletely 
or incorrectly folded proteins, arrest or unfold them and then either release them for 
spontaneous refolding or target them for degradation
22
. 
In the cytosol as well as in the Endoplasmic Reticulum (the two intracellular locations 
where protein folding occurs) two classes of chaperones can be found: general 
chaperones, which assist unfolded proteins by recognizing exposed hydrophobic 
patches, mobile loops, lack of compactness, or incomplete gycosylation, and private 
chaperones, which recognize a specific amino acid sequence or structure and bind 
devotedly to a specific protein (family), like for the chaperone RAP for the LDL-
receptor family
23
. 
Besides chaperones, the ER possesses various enzymes that assist proteins during 
folding: oxidoreductases which are involved in the formation and rearrangements of 
disulfide bonds
24
; Peptidyl-Prolyl-Isomerases (PPIases) which catalyze cis/trans 
isomerization of proline residues
25
. PPIases are extremely important in protein folding 
and their activity increase enormously the folding rate
26
. This is because the ribosome 
attaches amino acids in the trans conformation, which requires an isomerization step 
for all cis-prolines before the final folded structure can be achieved
26
. 
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In the ER a sensitive surveillance mechanism ensures the degradation of 
misfolded proteins 
 
The Endoplasmic Reticulum hosts the folding of important proteins such as antibodies, 
receptors and ion channels
27
. Incorrect folding of these proteins would be extremely 
harmful not only for the cell, but for the entire organism. To avoid such events of 
misfolding, a stringent quality control system operates in the ER and discriminates 
between correctly folded proteins and misfolded proteins [either (partially) unfolded or 
incompletely assembled protein complexes]
28
.  
Only folded proteins are exported toward their final destinations. Unfolded proteins, 
on the contrary, are retained in the ER by chaperones, that recognizes improperly 
misfolded proteins
29
. For example, protein carrying incorrect disulfide bonds are 
recognized as misfolded and retained for further folding, aided by molecular 
chaperones and folding catalysts such as protein disulfide isomerase 
30
. Prolonged 
retention of misfolded proteins in the ER leads to ubiquitin-mediated degradation by 
the ER-associated degradation pathway (ERAD)
31
. In the ERAD pathway, unfolded 
proteins are recognized as aberrant molecules by quality control receptors. These 
misfolded proteins are then sorted to an ER‐membrane‐associated 
dislocation/ubiquitination complex containing adaptor proteins that help retro-
translocation of the proteins into the cytosol, where they are polyubiquitinated and 
then degraded by the 26S proteasome
31
 (Fig. 3). 
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Figure 3. The general ERAD pathway for degradation of misfolded ER proteins. 
ERAD is initiated on the recognition of non-native proteins as aberrant molecules by 
the unfolded protein response (UPR) receptors. After being extracted from its folding 
path, the substrate is retro-translocated in the cytosol where proteins are poly-
ubiquitinated and then degraded from the proteasome (adapted from Douglas M. Cyr 
et al, 2009). 
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Accumulation of misfolded proteins can cause diseases 
 
Despite the presence of a highly active chaperone machinery, in some cases, misfolded 
proteins cannot be rescued. The presence of misfolded proteins (and especially their 
accumulation inside or outside the cells) can cause severe diseases
32
. These 
pathologies are referred to as “Conformational Diseases”32. Most of the time, 
misfolding is due to mutated amino acid residues that contributes negatively to the 
stability of a protein
32
. More rarely, mutations have been shown to stabilize folding 
intermediates which in turn slow down the folding process rate
32
.  
The deleterious effects of misfolded proteins may depend on protein loss of function
33
 
as observed in Cystic Fibrosis (CF) and Congenital Nephrogenic Diabetes Insipidus 
(cNDI). Cystic fibrosis is caused by mutations in both copies of the gene coding for 
the cystic fibrosis transmembrane conductance regulator (CFTR) protein
34
. Although 
several mutations in the CFTR sequence have been identified, the deletion of three 
nucleotides coding for the phenylalanine residue at position 508 (ΔF508 CFTR) 
accounts for 70% of patients diagnosed with CF
35. The ΔF508 allele of CFTR has been 
confirmed as a trafficking mutation that blocks maturation of the protein in the ER and 
targets it for premature proteolysis
36
. Similarly, congenital nephrogenic diabetes 
insipidus is caused by mutations of the arginine vasopressin receptor (V2R) that cause 
the trapping of the receptor in the ER
37
. Misfolded V2R is not expressed on the cell 
surface and this results in a receptor loss of function
37
. 
In other cases, deleterious effects of misfolded proteins may due to injurious ‘gain of 
function’ as seen in many neuro-degenerative diseases, in which protein misfolding 
results in the formation of harmful amyloid fibrils
33
. Among these pathologies there is 
the bovine spongiform encephalopathy (BSE), an infectious pathology whose 
infectious agent is a protein named prion scrapie or Prp
sc38
. Compared to Prp
c
, the wt 
uninfectious version of the prion protein, Prp
sc
 misfolds and forms fibrils that are toxic 
to the cells
39
. Moreover, Prp
sc
 is able to drive the conformational change of Prp
c
 
proteins that are
 
in its close proximity
40
. This conformational change can be also the 
result of mutations (single amino acid substitutions, deletions or insertions) of Prp
c 
primary sequence
41
. The beta-sheet content in Prp
sc 
 structure is higher than that of Prp
c
 
that, on the other hand, is mainly enriched in alpha-helical conformation
42
. 
Beta-sheet conformation seems to be a common feature of misfolded aggregated 
proteins and it seems the driving force for the formation of the toxic Prp
sc
 fibrils, as 
15 
 
well as of many other toxic fibrils
43
. Amyloid β peptide, α-synuclein and Hungtingtin 
form amyloid fibrils in Alzheimer’s disease (AD), Parkinson’s disease (PD) and 
Huntington’s disease (HD), respectively43. Beta-sheet conformation also exists in 
many functional native proteins such as immunoglobulin
44
, but the transition from 
alpha-helix to beta sheet is characteristic of amyloids deposits
45
. The abnormal 
conformational transition from alpha-helix to beta-sheet exposes hydrophobic amino 
acid residues and promotes protein aggregation
45
 (Fig. 4).  
There are different pharmacological approaches for conformational diseases. In some 
cases it is possible to protect the protein native state from misfolding and aggregation 
events
46
. For BSE, a therapeutic approach is being consisting in the development of 
antibodies which recognize and protect the native Prp
c
 against the negative interactions 
with Prp
s46
. 
In other cases it is possible to simplify the achievement of the correctly folded state. 
Recent studies have paved the way for the utilization of small molecules named 
Pharmacological Chaperones (PC)
47,48
. PC are able to enter the cell and interact with a 
protein to stabilize its native state and prevent its aggregation
48
.  
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Figure 4. Energy landscape of protein folding and misfolding. Protein folding 
and protein aggregation are competing reactions. During the folding process, the 
formation of energetically favorable intramolecular interactions (green) shifts the 
thermodynamic equilibrium towards the native conformations. However, proteins 
may adopt energetically favorable but non-native conformations that can slow 
down the folding process rate. These partially folded or misfolded states are 
prone to establish intermolecular interactions (red) which result in protein 
aggregation (amorphous aggregates, β-sheet-rich oligomers, and amyloid fibrils). 
Chaperones assist in overcoming the free energy barriers. Indeed, they inhibit 
intermolecular interactions and therefore promote folding to the native state 
conformation (adapted from Muntau et al. 2014). 
17 
 
Ligands act as pharmacological chaperones 
 
Binding of orthostatic or allosteric drugs to their target proteins may promote the 
folding of the latter by shifting the thermodynamic equilibrium towards the native 
conformation
49
. Native states together with folding intermediates, that are endowed 
with properly organized pockets, are the only conformations able to form ligand 
binding interactions. Ligand binding lowers the free energy of the proteins, increasing 
their stability
49
. Moreover, the low energy state of the ligand-protein complex 
minimizes off-pathway interactions preventing misfolding and aggregation
49
. 
Ligands have been shown to be successful in rescuing folding of membrane proteins 
and more specifically of GPCRs. Indeed, GPCRs explore a wide range of possible 
native conformations, all endowed with very similar energetic minima
50
. Such 
structure flexibility allows the binding of different class of ligands, all more or less 
able to stabilize their cognate receptor. For this reason, a large pool of candidates with 
a potential activity as PC have been identified. For example, β2AR-agonist promotes 
the folding of its cognate receptor by shifting the thermodynamic equilibrium towards 
the native state
51
 (Fig. 5). 
 
 
 
 
 
 
 
 
 
 
Figure 5. Agonist binding increases β2AR dynamics by decreasing the energy 
of intermediate and active states. G proteins further stabilize the active 
conformation and the formation of a signaling complex is required for the 
complete receptor transition to the active state (adapted from Nygaard, R et al 
2012). 
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In vitro, there are several demonstrations of ligands acting as PC with potential for 
therapeutic applications.  
Misfolded versions of the V2-vasopressin receptor causes the congenital nephrogenic 
diabetes insipidus (cNDI)
37
. Among these, the mutant R137H is retained in the ER and 
not expressed on the cell surface
52
. Treatment of cells transiently expressing V2 
mutants with the V2R antagonist SR49059, rescued the membrane localization and 
signalling efficiency of the mutant receptor
53
. Moreover, the SR49059 chaperone 
activity was tested in cNDI patients carrying R137H mutation
54
. Two-days after 
administration, SR49059 had beneficial effects on urine volume and osmolality, that 
are clinical parameters associated with a functional V2R. However, further clinical 
trials of SR49059 were abandoned because of its potential interference with the 
cytochrome P450 metabolic pathway
54
. 
Another study showed that the antagonist Ipsen 17 acts as PC of its cognate receptor 
melanocortin 4 receptor (MCR4)
55
. Mutations in MCR4 that cause intracellular 
retention of the receptor are the most common monogenic cause for obesity
56
. Ipsen 17 
rescued several intracellularly-retained MCR4 mutants, resulting in increased cAMP 
production upon agonist stimulation
55
. Thus, the ability of Ipsen 17 to rescue a wide 
variety of MCR4 mutants makes it particularly promising for therapeutic applications. 
However it has not yet been tested in animal models. 
Janovick et al. showed that a non-peptide antagonist of the gonadotropin releasing 
hormone receptor (GnRHR) could rescue folding and activity of five intracellularly 
retained mutants (T32I, E90K, C200Y, C279Y, and L266R)
57
. GnRHR mutations can 
affect the neural regulation of the reproductive system
58
. In a knock-in mouse model of 
hypogonadism, treatment with GnRHR agonists restore reproductive parameters, 
including spermatogenesis and androgen levels
59
.  
Other examples of G-protein-coupled receptors (GPCRs) whose ligands were shown to 
rescue the function of mutated receptors are: rhodopsin
60
, α1/β1/β2 adrenergic 
receptors
61
, luteinizing hormone receptor (LH) and glucagon receptor
62
.  
To date, known ligands of a protein were assayed for their pharmacological chaperone 
potential. Recently, we showed that the potential to rescue misfolded targets can be 
used as a readout in screening campaigns toward the identification of new ligands
63
. 
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RESULTS 
“Pharmacological Chaperone Readout” screening platform 
 
Recently we have set up a new screening platform named “Pharmacological 
Chaperone Readout” (PC-Platform)63. This platform allows to identify ligands in 
virtue of their ability to interact directly with the target and to affect its tridimensional 
structure (Fig. 6).  
By using PC-platform we have identified the first allosteric modulator of the Frizzled 
4 (Fz4) receptor, a member of the GPCR class F family. 
To identify ligands of Fz4 we have generated a cell line expressing a Fz4 mutant, Fz4-
L501fsX533, responsible in vivo for the occurrence of the Familial Exudative 
Vitreoretinopathy (FEVR), a pathology of the retina
64
. The frame-shift mutation 
L501fs533 dictates a change in the amino acidic sequence of the C-terminal tail of the 
receptor inhibiting its function. Moreover, the resulting mutant, here referred to as 
Fz4-FEVR, aggregates intracellularly in the ER without reaching the PM of the cell 
where, in contrast, the wt receptor localizes at steady state
65
.  
To identify Fz4 wt modulators, a library of organic molecules has been screened for 
pharmacological chaperones of Fz4-FEVR, i.e. for molecules able to rescue the 
folding and correct localization of Fz4-FEVR at PM. Using such read-out the organic 
molecule FzM1 has been thus identified as Fz4-FEVR pharmacological chaperone
63
.  
The pharmacological chaperone FzM1 acts as allosteric inhibitor of the Fz4-wt 
receptor, binding directly to the wt receptor and inhibiting the signalling pathway Fz4 
is involved in
63
. Structure-Activity Relation analysis performed using FzM1 as lead 
allowed us to identify the first allosteric agonist of Fz4, FzM1.8
66
.  
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Figure 6. Schematic representation of “Pharmacological Chaperone Readout” 
platform. 
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FzM1 acts as a pharmacological chaperone of the mutant Fz4 receptor 
 
The frameshift mutation that characterizes Fz4-FEVR C-terminal tail, affects receptor 
stability and induces its aggregation and retention in the ER
65
. Notwithstanding, Fz4-
FEVR localization at the PM can be rescued by overexpressing the protein chaperone 
α-B crystalline67. Fz4-FEVR can be thus included among the proteins that are 
responsible for conformational diseases whose phenotype can be rescued by strategies 
aiming to improve folding. The marked difference in localization between the wt and 
mutant receptor makes Fz4-FEVR an ideal platform to screen for folding chaperones 
by offering an unambiguous readout. 
In order to identify pharmacological chaperones of Fz4-FEVR, we used as biological 
platform Hek293 cells stably expressing (HA)-tagged wt Fz4 (HA-Fz4-WT) or Fz4-
FEVR (HA-Fz4-FEVR). As expected, immunofluorescence data showed that HA-Fz4-
WT was localized in the Golgi complex and at the PM, whereas HA-Fz4-FEVR 
appeared to be trapped intracellularly, mainly in the ER (Fig. 7 A). HA-Fz4-FEVR 
Hek293 expressing cells were treated with a library of molecules for 48h 
(Supplementary Table S1). Chaperone activity was then assayed by measuring the 
recovery of HA-Fz4-FEVR localization at the PM.  
We showed that FzM1 rescued HA-Fz4-FEVR PM localization with an efficiency of 
15% and with a half-maximum effective concentration (EC50) in the micromolar 
range (Fig. 7 A, B, C). FzM1 is an ureido derivative harbouring a phenol, a thiophene 
and a naphthyl functional groups (Fig. 7 B) 
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Figure 7. FzM1 rescues Fz4-FEVR PM localization in Hek293 cells. (A) Cellular 
localization of Fz4 and Fz4-FEVR expressed in Hek293 cells. Confocal 
immunofluorescence of non permeabilized (PM) and permeabilized (intracellular) 
cells showing PM and ER localization of Fz4 and Fz4-FEVR (green), respectively. 
(B) Chemical structure of FzM1. (C) Rescue of Fz4-FEVR localization at the PM 
upon FzM1 treatment. Confocal immunofluorescence of non permeabilized cells 
showing PM localization of Fz4-FEVR upon treatment with FzM1. Fz4-WT 
expressing cells are shown for comparison.  
A 
C 
 
B
 
 A 
FzM1 
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FzM1 binding site on Fz4-wt receptor 
 
We identified FzM1, a molecule acting as  pharmacological chaperone of the mutant 
receptor Fz4-FEVR. We then confirmed that the molecule selected by the screening 
platform indeed addresses our target. In order to do this we identified the FzM1 
binding site on Fz4-wt.  
To achieve our aim, we modified the original FzM1 molecule by adding a reactive 
alkyne moiety. This new compound was called FzM1alk (Fig. 8). Alkyne groups may 
receive nucleophilic attacks from sulfhydrylic or hydroxylic groups of amino acids and 
generate covalent adducts. Thus FzM1alk would bind to serines, threonines and 
cysteines located at its binding sites. 
HA-Fz4-WT Hek293 cells were cultured in the presence of FzM1alk. Fz4 was 
immunopurified, digested with trypsin and analyzed by LC/MS.  
HPLC profiles of samples from FzM1alk-treated cells and untreated cells were 
compared. These almost totally overlapped, with the exception of a fraction eluting 
with a retention time of 17.2 min and present only in samples obtained from FzM1alk-
treated cells (Fig. 9). Among the peptides eluting in this fraction, the one with an m/z 
of 1,386.9 Da corresponded, with a deviation (Δmass) of 1.6 Da from the theoretical 
mass, to amino acids 418–426 of Fz4 ICL3 (theoretical mass of 990 Da) carrying 
FzM1alk (molecular weight 398.5 Da) covalently linked either to S418 or to T425 
(Fig. 10 A theoretical mass [M-H-FzM1alk]+ of 1,388.5 Da). A peptide with this m/z 
was present exclusively in the FzM1alk-treated sample. In contrast, the peptides that 
co-eluted with it (Fig. 10 B) were not unique as they were also present in the untreated 
sample in similar abundances, and thus they were not further considered.  
Thus, the spectra indicated that FzM1alk interacted with Fz4 ICL3 by contacting at 
least S418 or T425. 
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Figure 9. LC/MS analysis of FzM1alk treated Fz4. HA-Fz4-wt Hek293 cells were 
treated with FzM1alk (10 μM) for 24 hours to be then lysed. After immunoisolation, Fz4 
was digested with Trypsin and analyzed by LC/MS. Comparison between FzM1alk 
treated vs untreated Fz4 MS spectra enables to identify peptides presenting FzM1alk 
covalently attached (ΔM= + 398.5 Da). HPLC profiles of FzM1alk treated (blue curve) 
and untreated samples (green curve). Absorbance at λ=254 nm FzM1alk (red curve) and 
untreated (magenta curve) samples are reported. The boxes shows an enlargement of the 
region (retention time from 16.0 to 18.0 min) where a difference in the two HPLC 
profiles could be identified;  
Figure 8. FzM1alkchemical structure. 
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A 
B 
Figure 10. LC/MS analysis of FzM1alk treated Fz4. (A) MS spectra of the 
FzM1alk treated sample fraction eluting at retention time of 17.2 minutes. (B) 
Amplitudes of peptides with the indicated m/z in FzM1alk treated (green bars) and 
untreated (red bars) samples. Among the peptides eluting between 16.0 and 18.0 min 
of retention time, the pick corresponding to m/z of 1386-1387 was the only one to be 
exclusively present in FzM1alk treated sample. 
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Binding of FzM1alk or FzM1 to Fz4 ICL3 should cause a change in solvent 
accessibility in this region of the receptor. These changes can be highlighted by 
measuring the rate of hydrogen-to-deuterium exchange (HDX) at this site.  
In the absence of FzM1, almost the entire receptor exchanged its hydrogen atoms with 
deuterium (with the exception of a helix of the ECD domain, amino acids 154–164; 
Fig. 11). As expected, the C-terminal tail and the ECD of the receptor showed the 
higher rate of exchange compared to the TMD (Fig. 12 A). Upon FzM1 binding, 
solvent accessibility of ICL3, TM5–7 and the C-terminal tail of the receptor was 
reduced, whereas the rest of the protein became more solvent accessible (Fig. 12 B). 
The burial of the ICL3 from solvent upon ligand binding appears compatible with 
ICL3 being contacted by FzM1 and with a change in the conformation of this loop. A 
burial of the C-terminal tail can be also hypothesized from the HDX data. The latter 
could be due to a tighter interaction of the tail with ICL3 or, more likely, as seen for 
many other GPCRs, with the tail interacting with the detergent micelles. 
We envisaged that the diminished solvent accessibility of ICL3 upon FzM1 binding 
could have been the mechanism behind the folding chaperone effect of the molecule 
on Fz4-FEVR. To verify this, we replaced ICL3 residues with alanines to affect the 
fold of this ICL and its interactions with the solvent. We mutated some amino acids in 
the FZ4-FEVR ICL3 to then test the effect of such mutations on the PM localization of 
the receptor. Notably, the resulting mutant receptor regained PM localization only 
when T425 and K426 of FZ4-FEVR were mutated (Fig. 13). Thus, by interfering with 
the interactions established between the solvent and the amino acid involved in FzM1 
and FzM1alk binding, we obtained the rescue of Fz4-FEVR folding and localization. 
By identifying the FzM1alk binding site at the ICL3 region, we proved that this 
pharmacological chaperone is indeed a ligand of Fz4-wt. FzM1 or FzM1alk binding 
induces a conformational change in Fz4-wt that reduces the solvent accessibility at the 
ICL3. Moreover, they act as pharmacological chaperones by stabilizing the Fz4-FEVR 
receptor and hampering its aggregation. Though the FEVR C-terminal tail induces 
Fz4-FEVR aggregation, ICL3 can counterbalance the effect of the tail, influencing the 
susceptibility of the full receptor to the aggregation. When FzM1 binds to ICL3 or 
T425A-K426A are mutated, the negative effects of the C-terminal tail on the entire 
receptor are compromised and the aggregation process is abolished. 
. 
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Figure 11. Analysis of FzM1 binding by HD exchange. Immuno-purified Fz4-wt, 
treated or not with FzM1, was incubated on ice with D2O to allow H to D exchange. 
The protein was then digested at low pH with Formic Acid and run on LC/MS (pH of 
the run less than 2.5 to minimize back exchange). Hydrogen to deuterium exchange 
rate (difference of peptide masses in D2O and in H2O) of Fz4 peptides in the presence 
(green bars) or in the absence (red bars) of FzM1. Peptides are indicated by their aa 
numbering and by their position in Fz4 (Extracellular Domain, (ECD)), 
Transmembrane Domain (TMD) and cytosolic tail (C-tail); 
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Figure 12. Analysis of FzM1 binding by HD exchange. (A) Rate of deuterium exchange 
(change of mass upon incubation with D2O, Da) in untreated Fz4. (B) Difference in rate of 
deuterium exchange upon FzM1 binding. The arrow indicates a possible movement of the 
C-tail toward the lipid bilayer. Segments in gray represent not detected peptides. 
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Figure 13. Cellular localization of HA-Fz4, HA-Fz4-FEVRand HA-
Fz4T425AK426A-FEVR transfected in Hek293 cells. Immunofluorescence of 
non permeabilized cells showing the PM localization of HA-Fz4-WT and 
HA-Fz4T425AK426A-FEVRbut not of HA-Fz4-FEVR. Scale bars, 10 μm. 
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FzM1 is an allosteric inhibitor of Fz4 
 
By identifying the FzM1 binding site, we proved that this pharmacological chaperone  
is a ligand of Fz4-wt. Next, we confirmed that FzM1 modulates Fz4-wt activity.   
Fz4 signaling pathway is activated by Wnt ligands. Wnt binding to Fz4 recruits the 
scaffold protein Dishevelled (Dvl) at the PM
68
. The complex Wnt-Fz4-Dvl inactivates 
the Adenomatous Polyposis Coli (APC) destruction complex [formed by Glycogen 
synthase kinase 3 (GSK3β), Axin, and Adenomatous Polyposis Coli] and leads to the 
intracellular accumulation and nuclear translocation of β-catenin. In the nucleus, β-
catenin regulates T-cell factor /lymphoid enhancer factor (TCF/LEF) dependent 
transcription of Wnt/ β-catenin target genes like cyclin D1, c-myc, and lgr568. 
We tested the ability of FzM1 to modulate the Wnt/β-catenin pathway with a 
luciferase assay that measures the TCF/LEF dependent transcription activation. We 
performed the assay on Hek293 cells transfected with HA-Fz4-wt. These cells do not 
express Fz4 endogenous ligands and, as expected, did not have a TCF/LEF basal 
activity. However TCF/LEF activity can be induced upon treatment with Norrin, an 
high affinity ligand of Fz4
69
. 
In absence of the Fz4 agonist Norrin, FM1 did not induce the TCF/LEF dependent 
transcription (Fig. 14 B). Thus, FzM1 did not act as a Wnt/ β-catenin pathway 
activator. 
On the contrary, after FzM1 treatment, Norrin-dependent TCF/LEF activation was 
abolished, suggesting that this molecule could be an inhibitor of the Wnt–β-catenin 
pathway (Fig. 14 A). 
We further confirmed the FzM1 activity as Wnt pathway inhibitor by using LiCl, a 
GSK-3β inhibitor, that causes the β-catenin nuclear translocation (Fig. 14 B).  
We also hypothesized the molecular mechanism behind Wnt pathway inhibition by 
FzM1. ICL3 is the region involved in the Dsh recruitment by Fz4. Contacting ICL3, 
FzM1 induced a conformational change of Fz4 which no longer was able to recruit 
Dvl, ultimately blocking β-catenin C-terminal phosphorylation played by CK1 and the 
consequent β-catenin nuclear translocation. 
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Figure 14. (A) Dose-response curve for FzM1 inhibition of Wnt signaling. 
Hek293 cells were transiently transfected with HA-Fz4-WT and treated with 
Norrin (40 ng ml−1) in the presence of the indicated concentrations of FzM1. 
Measurements were done in triplicate and are shown as mean ± s.d. RLE, 
relative luciferase expression. (B) Hek293 cells were transiently transfected 
with HA-Fz4-WT treated with LiCl (30 mM) and or with the indicated 
concentrations of FzM1. 
A 
B 
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FzM1.8, a FzM1 derivate compound, acts as an allosteric agonist  
 
We showed that FzM1 is an allosteric inhibitor of Fz4. With the aim to generate new 
Wnt/β-catenin pathway modulators we used FzM1 as lead compound to obtain a small 
library of FzM1 analogs.  
To evaluate the activity of the new compounds we used Hek293 cells transiently 
expressing both Fz4 and a Wnt reporter construct, the latter presenting the coding 
sequence of GFP under the control of an optimized Wnt Responsive Element (WRE-
wt). Compared to mock transfected cells, transient expression of FZD4 did not induce 
activation of the Wnt reporter construct indicating a low level of basal activity of 
FZD4 in the absence of ligands. In contrast, activation of Wnt/β-catenin canonical 
pathway by the GSK3-β inhibitor LiCl (Fig. 15 A-C) induced GFP expression and 
increases the fluorescence of the cells.  
We showed that the replacement of FzM1 thiophene with a carboxylic group  
transformed FzM1 in to a new allosteric agonist of Fz4. In the absence of any 
orthosteric ligand, the new compound 3-Hydroxy-5-(3-(naphthalen-2-yl)ureido) 
benzoic acid (FzM1.8, Fig. 16 and Fig. 17 A, B) was able to increase WRE activity in 
Fz4 expressing Hek293 cells.  
Similarly to FzM1, FzM1.8 did not increase WRE activity in cells not expressing Fz4 
(Fig. 17 C-D) indicating that the effect of the compound is Fz4 dependent. Moreover, 
FzM1.8 did not induce GFP expression in cells transiently expressing both Fz4 and 
either a mutated nonfunctional WRE reporter (WRE-mut, Fig. 17 E-F). These results 
confirm that FzM1.8 does not act as general transcriptional activator and that, instead, 
its activity relies on a functional WRE. Interestingly, in the range of concentrations 
tested, FzM1.8 modulated WRE activity with values fitting hormetic dose-response 
curves (described in Equation1). We measured both a stimulatory (EC50 of activation 
(logEC50act) ± s.e.m.=-6.4 ± 0.2, n=16) and an inhibitory activity (EC50 of inhibition 
(logEC50inh) ± s.e.m. = -5.5± 0.1, n=16) (Fig. 17 B).  
Despite presenting a switch in its activity, FzM1.8 contacts the same binding sites of 
the original lead. As already shown for FzM1, Hek293 cells transfected with the Fz4 
mutant FZD4T425A only partially responded to FzM1.8 treatment (Fig. 18). 
Moreover, HDX analysis reveals that FzM1.8 binding reduced solvent accessibility of 
ICL3. Interestingly, both the ligands affected the conformation of TM6, with FzM1.8 
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increasing the solvent accessibility of this section of the receptor more than FzM1.8 
(Fig. 19).  
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Figure 15. Experimental platform used to measure Wnt/β-catenin pathway activity. 
(A) Schematic cartoon depicting Fz4 involvement in Wnt/β-catenin pathway; (B) Hek293 
cells transfected with the constructs WRE-wt and WRE-mut (Merge of Bright Field and 
GFP channel, Bar = 50μm). Activation of the pathway by LiCl induces GFP expression in 
cells transfected with WRE-wt but not in those transfected with mutated nonfunctional 
WRE (WRE-mut); (C) The histogram shows the increase in WRE activity after treatment 
with LiCl. [Values are reported as mean +/- s.e.m. (n=5) *P<0.05]. 
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Figure 17. FzM1.8 is an allosteric agonist of Fz4 and activates the Wnt/β-catenin 
pathway. (A-B) Dose-response curves for FzM1 and FzM1.8 modulation of Wnt/β-
catenin pathway in Hek293 cells co-transfected with both Fz4-wt cDNA and the WRE-wt 
reporter construct. Values indicate changes in the WRE activity (expressed as the 
percentage of change over basal activity). (C-D) Dose-response curves for FzM1 and 
FzM1.8 modulation of WRE activity in Hek293 in the absence of Fz4; (E-F) Dose-
response curves for FzM1 and FzM1.8 modulation of WRE activity in Hek293 cells co-
transfected with Fz4-wt and WRE-mut. 
Figure 16. Chemical 
structure of FzM1.8 
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Figure 19. FzM1.8 addresses Fz4 ICL3. Solvent accessibility of Fz4 upon binding to 
DMSO, FzM1 or FzM1.8 measured by HDX analysis. The color scale reflects the level of 
deuterium exchange measured as difference in peptide mass in the presence or in the 
absence of vehicle or of ligands. The arrows indicate the ICL3 and the TM6 of Fz4 and the 
level of deuteration upon vehicle, FzM1 or FzM1.8 binding. Numbers indicate TMD 
helices (5–6) and the C-terminal tail helix (8). 
Figure 18. Dose-response curves for FzM1.8 modulation of WRE activity in Hek293 
cells expressing Fz4-wt (red curve) or FZD4-T425A (black curve); 
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FzM1.8 mechanism of action 
 
We showed that FzM1.8, upon binding to Fz4, initiates a signaling route resulting in 
an increased WRE activity. Thus, we started testing if FzM1.8, by either affecting 
Fz4/Dvl interaction or by inhibiting β-catenin proteasomal degradation, was acting via 
Wnt canonical pathway (Fig. 20 A).  
As shown in Figure 20 B, in the presence of FzM1.8, Fz4 is still able of recruiting Dvl. 
Furthermore, differently from Wnt ligands or LiCl, FzM1.8 did not increase 
intracellular levels of β-catenin (Fig.  20 C). Finally, in the presence of CIK 7, a pan-
inhibitor of Casein Kinase I
70
, a protein involved in activation of the Fz4/Dvl 
complex
71
, FzM1.8 stimulatory activity was mostly preserved (Fig. 20 D). Thus 
FzM1.8/Fz4 complex stimulates WRE activity but does not affect proteins taking part 
in the Fz4/Dvl/APC axis. 
To explain FzM1.8 activity, we thus hypothesized the involvement of a non-canonical 
pathway. The only pathway that has been so far described as positive modulator of the 
Wnt canonical pathway is the one involving Phosphatidylinositol-4,5-bisphosphate 3-
kinases (PI3Ks)
72
. PI3K has been already shown to affect Wnt canonical pathway on 
multiple levels. In differentiated myofibers, binding of the orthosteric ligand Wnt7a to 
Fz7 directly activates PI3K pathway and induces myofiber hypertrophy
73
. Moreover, 
via AKT, PI3K inhibits GSK3-β and leads to β-catenin stabilization74. Alternatively, 
AKT has been shown to promote the activity of the histone acetyltransferases CBP and 
P300, both trans-activators of the β–catenin/TCF transcription complex75. These 
remodel the chromatin-bound to Wnt responsive genes, ultimately boosting the 
activity of the β–catenin/TCF transcription complex. Indeed, in the presence of the 
PI3K inhibitor LY294002
76
, FzM1.8 lost its ability to induce WRE activity (Fig 21 A). 
WB analysis of cell treated with FzM1.8 revealed an increase in AKT phosphorylation 
at Thr308 upon 30 min and 2 hour of incubation with the ligand, confirming the 
involvement of PI3K in the pathway activated by FzM1.8. Differently, we did not 
measure an increase in AKT phosphorylation at Ser473 (Fig. 22 A, B). Finally, 
Hek293 cells expressing both Fz4 and the AKT dominant negative mutant AKT 
K179M were insensitive to FzM1.8, further proving the involvement of the protein 
kinase in the WRE activation elicited by the ligand (Fig. 22 C). 
Since FzM1.8 does not induce β-catenin stabilization (Fig. 20 C) we tested whether 
WRE activation by FzM1.8 was dependent on CBP/p300. In the presence of the 
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CBP/p300 specific inhibitor I-CBP 112
77
, FzM1.8 activity was drastically reduced 
(Fig. 21 B) confirming the involvement of PI3K and CBP/p300 downstream the 
pathway activated by FzM1.8. The involvement of CBP/p300 indicates also that the 
Fz4/PI3K axis elicited by FzM1.8 is “ancillary” to the canonical Wnt pathway. Even if 
it bypasses the Wnt/Fz4/APC canonical route, the Fz4/PI3K axis acts ultimately on the 
nuclear pool of β-catenin (Fig. 21 C). 
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Figure 20. FzM1.8 does not affect canonical Wnt/β-catenin pathway. (A) Schematic 
cartoon depicting Fz4 involvement in Wnt/β-catenin pathway and the molecular target of the 
Casein Kinase I inhibitor CKI-7; (B) Non-confocal immunofluorescence showing 
recruitment of Dvl-GFP at the PM of HuH7.5 cells, in the presence or not of Fz4-wt and of 
the indicated amount of FzM1.8; (C) The histogram shows the intracellular levels of β-
catenin measured in Fz4 expressing Hek293 cells upon treatment with LiCl (30 mM) or the 
indicated amount of FzM1.8; (D) Dose-response curves for FzM1.8 modulation of WRE 
activity in cells expressing Fz4-wt in the presence of CKI-7; [Values are reported as mean 
+/- s.e.m. (n=5) *P<0.05]. 
Log[FzM1.8] 
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Figure 21. Fz4/FzM1.8 complex activates PI3K. (A-B) Dose-response curves for FzM1.8 
modulation of WRE activity in cells expressing Fz4-wt in the presence of either PI3K (A)  
or CBP/p300 (B) inhibitors; (C) Schematic cartoon depicting Fz4 involvement in 
Wnt/PI3K pathway. [Values are reported as mean +/- s.e.m. (n=5).*P<0.05]. 
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Figure 22. FzM1.8 signaling involves AKT. (A) Intracellular levels of AKT 
phosphorylated at Thr306 (P-Thr306), or at Ser473 (P-Ser473) in Hek293 cells transfected 
with Fz4 and treated for the indicated period of times with FzM1.8 (2 μM) or with the 
corresponding amount of vehicle (DMSO). In A the ratio between Phosphorylated and total 
AKT are indicated for each condition. [Values are reported as mean +/- s.e.m. (n=3)]. Panel 
B shows sections of gels representative of the replicates used for the quantification reported 
in A. The intensity of each band was normalized by decorating each filters with an anti α-
tubulin antibody. Only the relevant portion of the gels are shown. (C) Dose-response 
curves for FzM1.8 modulation of WRE activity in Hek293 cells co-transfected with Fz4-wt 
and with the dominant negative AKT mutant AKT-K176M. [Representative of three 
independent experiments]. 
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Effects of FzM1 and FzM1.8 on tumor cells 
 
We also investigated if FzM1 and FzM1.8 by modulating the Fz4 receptor activity 
could affect cancer cells growth. Indeed, the intracellular signaling pathway activated 
by Fz4 culminates in the activation of genes that have been related to tumor cell 
survival, differentiation and invasiveness
78
.  
As first we looked at the effects of FzM1 treatment on growth, differentiation and 
migration of U87MG glioblastoma cells. Fz4 expression in these cells has already 
been shown to relate to invasiveness and the differentiation state of the cells
79
. This 
cell line, when cultured in dish, arranges to form neurospheres that are spherical cell 
clusters containing cells positive for Nestin, a neural stem cell marker (Fig. 23 A, B). 
Treatment with FzM1 hampers neurosphere formation and induces cells to acquire a 
more elongated or neuronal appearance (Fig. 23 and Fig. 24). Moreover, FzM1 
reduces the number of cells positive for Nestin, suggesting that, upon FzM1 treatment, 
U87MG cells transitioned toward a more differentiated phenotype (Fig. 25 A, B).  
We confirmed the ability of FzM1 to act as inhibitor of tumor cell growth in intestinal 
Caco2 cell line. Similarly to U87MG cells, Caco2 cells are known to rely on an active 
Fz4-dependent pathway to maintain their undifferentiated proliferative state. FzM1 
treatment promotes differentiation of Caco2 cells as shown by the marked change in 
their morphology (increase in cytoplasm volume) and by the expression of the 
differentiation marker E-cadherin (Fig. 26 A, B).  
We also evaluated the effects of FzM1.8 treatment on Caco2 cell line. Differentially 
from FzM1, FzM1.8 does not change the differentiation state of these cells. However, 
the treatment causes an increase of the cells duplication rate (Fig. 27 B). Thus, we 
investigated if FzM1.8 influenced the Fz4-depedent gene regulation. We showed that 
FzM1.8 causes a Fz4-dependent upregulation of genes stimulating cell proliferation 
such as c-myc and cyclin-D (Fig. 27 A, B). On the contrary, FzM1.8 treatment does 
not induce changes in the colon stem cell marker lgr5, indicating the FzM1.8 actives 
Fz4 pathways that stimulates proliferation preserving stemness of the cells (Fig. 27 A, 
B). It has been further showed that the ability of FzM1.8 to activate Fz4 plays an 
important role in tissue repair lung cells
66,80
. Indeed, Fz4 is a positive modulator of cell 
proliferation and wound healing, crucial processes involved in tissue repair.  
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FzM1 
Figure 23. Effects of FzM1 treatment on U87MG glioblastoma cells.  (A) 
U87MG cells were cultured in presence of vehicle (DMSO 0,1%) or FzM1 (10 
µM). β-catenin is in green and nuclei are in blue (DAPI). Immunofluorescence 
shows vehicle-cells form peculiar neurospheres; upon compounds treatment they 
disassemble. Scale bar: 20µm. (B) U87MG cells immunofluorescence, β-catenin 
is in green and nuclei are in blue (DAPI). FzM1 treatment reduces dimension of 
neurospheres. Scale bar: 20µm. 
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FzM1 vehicle 
 
 
Figure 24. Morphological effect of FzM1 on U87MG cells . FzM1 (10 µM) 
affects U87MG cell morphology. Upon treatment, cells acquire a more 
differentiated phenotype. Bright field images show nuclei. Scale bar: 100 µm  
 
 
 
 
B 
Figure 25. FzM1 influences on U87MG differentiation. (A) Immunofluorescence 
shows  neural stem cell marker  nestin  in green and nuclei in blue (DAPI). FzM1 
treatment reduces the number of nestin-positive  U87MG cells. Scale bar: 100 µm (B) 
Upon FzM1 treatment U87MG cells show radical decrease of: % of  Nestin-positive 
cells, neurosphere average diameter and number of neurospheres.  
 
 
FzM1 vehicle 
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Figure 26. Effects of FzM1 on Caco2 differentiation. (A) FzM1 accelerates CaCo-2 cell 
differentiation. CaCo-2 cells were treated with vehicle (DMSO 0.1%, 3 d) or with FzM1 
(10 μM, 3 d). Upon treatment, cells acquire a more differentiated phenotype (β-catenin is 
in green). Scale bars, 20 μm. (B) Quantification of differentiation of CaCo-2 (number of 
cells changed in morphology, E-cadherin–positive and β-catenin–positive cells) upon 
treatment with FzM1 (10 μM, 3 d); n = 3, data represent mean ± s.e.m. 
FzM1 vehicle 
A 
 
B 
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Figure 27. FzM1.8 increases proliferation of undifferentiated colon cancer cells. 
(A) The effect of FzM1.8 or FzM.1 on the expression levels of genes regulated by 
Fz4 signalling pathway. Genes stimulating cell proliferation such as c-myc and 
cyclin-D are up-regulated. (B) Duplication rate of human colonic biopsies in culture 
medium supplemented with FzM1, FzM1.8 or with vehicle. 
 
 A 
B 
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DISCUSSION 
 
There are several evidences of the ability of ligands to act as pharmacological 
chaperones in rescuing the folding of their target proteins. We proved that, by 
transitive property, the potential to rescue misfolded targets can be used as a readout in 
screening campaigns toward the identification of new ligands. We screened a library 
of small molecules for their ability to rescue the ER-trapped folding defective mutant 
of Fz4, Fz4-FEVR. In this way we identified FzM1, the first allosteric modulator of 
Fz4 that physically interacts with the ICL3 of Fz4. In our opinion, the change in the 
conformation of ICL3 upon FzM1 binding is the mechanism behind the 
pharmacological chaperone activity it exerts on Fz4-FEVR. Fz4-FEVR bound to 
FzM1 is more resistant to receptor aggregation and is properly transported to PM. 
Interestingly, we showed that FzM1.8, that is an analog of FzM1, is not able to act as 
pharmacological chaperone of Fz4-FEVR. However, FzM1.8 acts as a positive 
allosteric modulator of Fz4-wt. Thus, the PC-platform seems to select ligands binding 
the inactive state conformations (such as antagonist and negative allosteric modulator) 
rather than the active state conformations of GPCRs (such as agonist and positive 
allosteric modulators). The active-state conformations of GPCRs are higher in energy 
(less stable) than inactive-state conformations
50
. Moreover, it has been shown that 
agonist binding even does not stabilize a unique native conformation
51
. In contrast, it is 
associated with conformational heterogeneity that may be important to regulate several 
alternative pathways
51
. In our opinion, these could be the reasons why agonist and 
positive modulators fail in counterbalance the mutant protein tendency to aggregate 
and have been thus never identified with our PC platform.  
PC-platform represents a useful alternative to traditional screenings. It might be 
especially useful in the case of protein targets difficult to purify in large quantities and 
proteins with unclear, unknown or even absent connections to signaling cascades, such 
as orphan GPCRs. Furthermore, we have already shown that the applicability of the 
platform can be extended also to the receptors for which mutations inducing 
misfolding and aggregations are not known. Indeed, we proved that appending the 
mutated tail of Fz4-FEVR to other TM proteins is sufficient to determine the unfolding 
of the chimeric proteins and their ER retention
65
. Finally, GPCRs would represent 
good candidates for PC-platform. Indeed, they are highly dynamic and can exist in a 
multitude of distinct conformations that allow the binding of different class of ligands.   
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MATERIALS AND METHODS 
 
Reagents. Salts and organic solvents are from Sigma Aldrich (USA) and Applichem 
(Germany), are handled according to manufacturer instructions. 
Cell culture. Hek293 cells and U87MG were cultured in RPMI medium and DMEM 
(Dulbecco’s Modified Essential Medium), respectively, supplemented with 10% FBS 
(Fetal Bovine Serum), Glutamax and Pen/Strep antibiotics. Transfections were 
performed with polyethylenimine (PEI) according to the manufacturer’s protocol. HA-
Fz4-WT cell clones are obtained by transfecting Hek293 cells with the corresponding 
cDNA cloned in pcDNA 5.0, kind gift of B.T. Mac Donald (Harvard medical School). 
Antibodies. The following antibodies were used: mouse monoclonal anti-HA peptide 
(HA-7), (code: #H3663 Sigma-Aldrich) was used at 1/2,000 dilution for both western 
blotting (WB) and immunofluorescence (IF) while a 1/200 dilution was used for 
immunoprecipitation (IP); mouse monoclonal anti- α-tubulin (10D8, code: sc-53646, 
Santa Cruz biotechnology, Santa Cruz, CA, USA) (WB: 1/200); rabbit polyclonal anti- 
β-catenin (H-102, sc-7199, Santa Cruz biotechnology) (WB: 1/1,000); rabbit 
polyclonal anti- HA peptide, ( code: H6908Sigma-Aldrich) (WB: 1/2,000; IF : 1/500, 
IP: 1/500); rabbit anti- AKT (#9272, Cell Signaling Technology, USA) (WB: 1/1000); 
rabbit anti- Phospho-AKT (Thr308) (D25E6, #13038, Cell Signaling Technology, 
USA) (WB: 1/2000); rabbit anti- Phospho- AKT (Ser473) (D9E, #4060, Cell Signaling 
Technology, USA) (WB: 1/2000); goat anti-rabbit IgG (H&L), DyLight 594 
conjugate, (code: GtxRb-003-D594NHSX, Immuno- Reagents, Inc. Raleigh, NC, 
USA) (IF:1/500); Donkey anti- Rabbit IgG (H&L), HRP conjugate, (code: DkxRb-
003- DHRPX, ImmunoReagent, Inc.) (WB: 1/4,000), goat anti- Mouse IgG (H&L), 
DyLight 594 conjugate, ( code: GtxMu- 003-D594NHSX, ImmunoReagent, Inc.) (IF: 
1/500 dilution for); goat anti-Mouse IgG (H&L), HRP conjugate, (code : GtxMu-003-
DHRPX ImmunoReagent, Inc.) (WB: 1/4,000). 
DNA-All DNA constructs were synthesized at Gene Script (USA). The cDNA coding 
for N terminally HA-tagged FZD4wt (HA-FZD4-wt), and for the mutants HA-FZD4- 
T425A and HA-FZD4-T425D were all cloned in the expression vector pCDNA3.1 
(Invitrogen). For the reporter construct WRE-GFP-wt: 8 repeats of the optimized 
TCF/LEF binding sequence [5’-AGATCAAAGGGG-3’] (interspaced by the triplet 5’-
GTA-3’) were positioned upstream to a minimal TATA box promoter [5’- 
tagagggtatataatggaagctcgaattccag-3’] and a KOZAC region [5’-
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cttggcattccggtactgttggtaaaaagcttggcattccggtactgttggtaaagccacc-3’]. The sequence was 
cloned in the vector pCDNA 3.1 (+) GFP between the restriction sites for NruI and 
HindIII. This replacement substitutes the CMV promoter of the original vector with 
the TCF/LEF responsive sequences. The correctness of the sequences was verified by 
DNA sequencing. The control reporter construct WREGFP-mut was obtained by 
mutagenesis of WRE-GFP-wt and presents the 8 repeats of the TCF/LEF binding 
sequence mutated to [5’-AGGCCAAAGGGG-3’]. A reporter construct ( cmv-GFP) 
presenting GFP under the control of the cmv promoter was used as control. The 
plasmid necessary for the expression of the human AKT mutant AKT-K179M was 
kindly provided by Prof. G. Condorelli (Naples, Italy). 
Immunofluorescence. Cells were grown up on glass coverslips and then were fixed in 
3,7% formaldehyde/PBS pH 7.4 freshly made for 30 minutes at room temperature 
(RT). Formaldehyde was quenched by incubating the coverslips for 30 minutes in 0.1 
M glycine/PBS. Cells were permealized in 0.1% Triton/PBS pH 7.4 for 10 minutes at 
RT. Glass coverslips were then incubated with primary and secondary antibodies 
diluted in PBS for 1 h and 30 min at RT, respectively. After fixing coverslips with 
glycerol/PBS 1:1 on slides, cells were analyzed with a Leica TCS-SMD-SP5 confocal 
microscope. 
Compound synthesis. FzM1 FzM1alk and FzM1.8 were synthesized following a 
procedure of urea derivatives formation by reacting amines and isocyanates. HNMR, 
CNMR, FTIR spectroscopy and HRMS were used to confirm of the compounds. The 
synthesis of the FzM1 analogues was realized in cooperation with Professor Romano 
Silvestri’s research group at University “La Sapienza” in Rome. 
Immunoisolation from cultured cells and trypsin digestion. Cells were lysed in B 
buffer (Hepes K-OH 50mM, 150 mM NaCl, 1% Triton X-100, supplemented with 
protease inhibitors). Lysates were centrifuged at 14,000 r.p.m. to remove cell debris 
and unbroken cells. Clarified lysates were incubated overnight with antibody at 4 °C, 
followed by treatment with Protein A–coupled Sepharose (45 min, 4 °C). Samples 
were extensively washed in B buffer and then resuspended in 40 μl of buffer 
containing trypsin and incubated overnight at RT. 20 μl of the tryptic digestion were 
processed for LC/MS. 
HDX. Immunoisolated Fz4 (still bound to the Sepharose beads) was incubated in B 
buffer at 4 °C in the presence of or without ligand (10 μM concentration). After 30 
min, beads were resuspended in 40 μl of D20 for 1 min in the presence of or without 
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ligand. Formic acid was then added (5% final concentration), and the samples were 
boiled four times at 95 °C for 15 min. DTT (50 mM) was added to reduce disulfide 
bonds. 20 μl of the tryptic digestion were processed for LC/MS. 
HPLC/MS. All samples were analyzed by analytical HPLC/MS (Agilent 1200 series 
HPLC system, Agilent 1260 UV-vis detector Infinity and Agilent Quadrupole 6110 
LC/MS) equipped with a C18-bounded analytical reverse-phase HPLC column (Vydac 
218TP104, 4.6 × 250 mm) using a gradient elution (10–90% acetonitrile in water 
(0.1% TFA) over 20 min; flow rate = 1.0 ml/min. For HDX experiments, the gradient 
buffer was kept at a pH lower than 2.5 (to reduce back exchange) by adding formic 
acid. 
LC/MS spectra analysis. LC/MS spectra were analyzed with MetAlign51 with the 
following settings: mass resolution/BIN (nominal mass mode, 0.65), peak slope factor 
(5× noise), peak threshold factor (5× noise), peak threshold abs. value (150), average 
peak width (three scans), autoscaling on total signal, tuning alignment (prealign 
processing iterative, mass peak selection set on min. factor (5× noise). Amplitudes of 
masses coming from treated and untreated samples were subtracted to identify mass 
exclusively present in each of the samples. Masses were assigned with Mascot 
(MatrixScience)52. Samples containing only trypsin or protein Sepharose or antibody 
were run as controls. 
Statistical analysis. EC50 was calculated by fitting direct total binding data by 
nonlinear regression analysis of dose-response curve using Prism software 
(GraphPad). All data were analyzed using the two-tailed Student’s t-test. P < 0,05 were 
considered statistically significant. 
FZD4 receptor model. FZD4-wt three-dimensional model was built using the CCP4 
suite. Crystal structure of the cysteine-rich domain of FZD8 (Protein Data Bank (PDB) 
code 4F0A) and the TMD of Smoothened receptor (PDB codes 4NAW and 4JKV) 
were used as templates for ECD and TMD and ILC of FZD4, respectively. 
TCF/LEF activity measurement using the WRE-GFP constructs. Hek293 cells 
were seeded (5 x 103 per well) in 96-well black Optyplates (Perkin Elmer). After 24 
hours, cells were co-transfected with both WRE-GFP-wt (or when indicated WRE-
GFP-mut) and HA-FZD4-wt. Transfection mixtures were prepared as follow: for each 
well 0,25μg of PEI (pH 7.0) was supplemented with 0,08 μg of DNA(both diluted in 4 
μl of DMEM). The mixture was incubated at room temperature for 30 min to be then 
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diluted in culture medium and added to the cells. 24 hours after transfection, the 
medium was replaced and cells incubated with FzM1, FzM1.8 at the indicated 
concentrations and for the indicated times. When reported, cells were supplemented 
with either CKI 7 dihydrochloride (5μM), NFAT inhibitor (10μM), 
Bisindolylmaleimide II (7,5μM ), Ly294002 (10μM), Suramin Hexasodium salt 
(10μM), Gallein (10μM), I-CBP 112 ( 7,5μM ) or Neomycin (500μM). At the end of 
the incubations, cells were fixed in 3.7% formaldehyde in PBS pH 7.4 for 30 min. 
Formaldehyde was quenched by incubating the cells for 30 min in 0.1 M Glycine in 
PBS 1X. The activity of the compounds was evaluated by measuring GFP expression.  
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Chapter 2 
INTRODUCTION 
Orphan GPCRs  
 
The superfamily of GPCRs includes at least 800 seven-transmembrane receptors, all 
participating in the most diverse physiological and pathological functions
81
. 
Approximately 36% of marketed pharmaceuticals drugs target human GPCRs, the 
most successful targets of modern medicine
81
.  
While for a conspicuous number of GPCRs drugs have been identified, optimized and 
tested in clinical trials, for more than 90 GPCRs drug discovery is still at the stage of 
identifying their endogenous ligands and their biological functions
82
. These so-called 
“orphan” GPCRs (OrphGs) have been involved in many types of cancer and rank 
among the most interesting future pharmacological targets
81
. Identification of their 
endogenous ligands is an unquestionable missing milestone of science, necessary to 
start the characterization of these unexplored receptors. The worldwide scientific plan 
to identify OrphGs’ endogenous ligands is referred to as “GPCRs deorphanization”83. 
Its anticipated outcome is to fully describe the structure, the biology and the 
physiology aspects of this interesting pool of pharmacological targets. 
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Orphan GPCRs and Glioblastoma 
 
While science is still looking for OrphGs’ endogenous function, their involvement  in 
cancer is fully clear. Recently it has been shown that several OrphGs are specifically 
overexpressed in several forms of cancer, among which Glioblastomas
84
. 
Glioblastomas (World Health Organization (WHO) grade IV astrocytomas) are highly 
aggressive infiltrating brain tumors and represent more than 50% of all gliomas
85
. At 
the cellular level these tumors are constituted by a variety of cells in different states of 
differentiation and are enriched in cancer stem cells (CSCs)
86
. Topoisomerase and 
tyrosine kinase inhibitors, alkylating and intercalating agents are examples of 
compounds nowadays used to treat glioblastoma
87,88
. However, classical radiotherapies 
and chemotherapies act preferentially on highly proliferating cells and thus spare 
CSCs, which are able to enter in a quasi-quiescent state and escape treatments
86
. The 
severe morbidity and mortality of glioblastoma heightened the search for new drugs 
acting on new targets different from those explored so far. The search for new 
treatments has uncovered several G protein-coupled receptors (GPCRs) as candidates 
and generated a growing interest in this class of proteins as alternative therapeutic 
targets for the treatment of Glioblastoma
84,89
. 
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CELSR2: an orphan GPCR overexpressed in Glioblastoma 
 
CELSR2 [Cadherin-EGF-LAG-Seven Pass-G-type receptor 2 (uniprot:Q9HCU4)] is 
an orphan GPCR overexpressed in Glioblastoma. It belongs to class B GPCRs, also 
known as adhesion GPCRs (aGPCRs)
84
. This indicates the presence in their long 
extracellular domain (ECD) of sequences of repeated domains, each acquiring folds 
proper of adhesion molecules. Human CELSR2 has an extracellular domain of 2350 aa 
and contains 9 Cadherin repeats, 7 EGF-like domains, 2 Laminin G-like domains, one 
Laminin-EGF-like domain and one hormone receptor motif (HormR). The ECD is 
followed by the canonical GPCR transmembrane assemblement with 7 transmembrane 
(TM) helices linked by 3 intracellular and 3 extracellular loops. ECD and the first 
transmembrane are joint together by a GPCR self-proteolysis site (GPS)
90
. 
The CELSR2 cadherin domain presents 110 amino acid residues and contains the 
sequences responsible for extracellular calcium binding
91
. In most of the proteins in 
which are present, cadherin domains are involved in the formation of trans/cis dimers, 
with these interactions requiring calcium coordination. However, that this can be 
applied also to CELSR2 cadherin domains remains to be proved. Shima et al.
92
 
obtained important mechanistic insights into the molecular function of CELSR2 
ectodomain. They expressed siRNA targeting CELSR2 in brain neurons and showed 
that CELSR2 loss of function caused dendritic simplification. Then, they expressed 
several deletion forms of CELSR2 to understand which domain of CELSR2 would 
have been able to rescue the phenotype and proved that the presence of the cadherin 
domain was essential for rescuing it 
92
. Further experimental evidences showed that the 
isolated CELSR2 cadherin domain (CELSR2-CR) when applied to hippocampal 
primary neurons enhanced neurite growth. Interestingly, the neuronal phenotypic 
effects of CELSR2-CR were lost in CELSR2 knockdown cells, proving that 
homophilic interactions CELSR2-CR/CELSR2 were necessary for activation of 
endogenous CELSR2 proteins
93
. CELSR2-CR acts also as a ligand for CELSR2 
proteins, evoking an increase of the intracellular calcium
93
. Further investigations on 
CELSR2 calcium-regulated cis/trans-dimerization are however necessary to explain in 
detail this potency of CELSR2 cadherin domains to activate receptor signaling.  
Seven EGF-like domains (EGF) separated by two laminin G (LAG) domains follow 
the CELSR2 cadherin repeats, both potentially able to bind calcium. Each EGF-CA 
domain contains about 40 amino acids, and the LAG domain acquires a jelly roll 
structure
94
. Downstream to the EGF-CA and LAG domains, CELSR2 contains an 
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EGF-laminin domain of approximatively 60 amino acids with 8 conserved cysteines. 
At the C-terminus of these repeats there is an hormone receptor motif (HormR) which 
contains conserved tryptophans and cysteines
95
. The HormR domain is a common 
feature of adhesion GPCRs. Even if it is often regarded as a potential binding domain 
for hormones 
96
, the essential N-terminal α-helix responsible for hormone interaction is 
missing in all the adhesion GPCRs, suggesting a structural more than a functional 
activity for this domain.  
At the membrane-proximal region of CELSR2, a GPCR Autoproteolysis-Inducing 
(GAIN) domain (320 residues) contains the GPCR proteolysis site (GPS) of 
approximatively 50 amino acids. The GAIN is the most highly conserved feature of 
aGPCRs
97
. The crystal structure of the aGPCR Latrophilin-1 GAIN domain revealed 
that it is organized in two subdomains: a α-helical and a β-sandwich subdomain 97. The 
α-helical subdomain interacts with the HormR domain in a manner that would block 
the interaction of homologous HormR domains with hormones. The GPS motif 
comprises the last five β-strands of the GAIN domain, and the cleavage occurs 
between the last two β-strands95,97 (Fig. 28). In vitro, proteolytic cleavage occurs 
through an intramolecular self-catalytic reaction between a conserved aliphatic residue 
(usually leucine) that acts as a general base and a threonine, serine or cysteine that acts 
as a nucleophile (L↓T/S/C)98. Interestingly, only human CELSR2 has the general base 
H2355 and the nucleophile T2357 suggesting that cleavage can be dispensable for the 
protein function. The cleavage occurs through a series of nucleophilic attacks and 
subsequent generation and hydrolysis of an ester intermediate. This process takes place 
in the Endoplasmic Reticulum (ER) and gives rise two fragments, an extracellular and 
a 7-TM subunits, that associate non covalently as a heterodimer. Although for several 
aGPCRs the proteolysis is an essential step for protein maturation and activity 
99
, 
recent studies have suggested that for some aGPCRs proteolysis is not necessary, and 
an intact GPS has structural meaning for the receptor 
100
. The functional importance of 
the GPS is also underlined by the association between two GPS point mutations of an 
another class B GPCR, GPR56, with the bilateral front parietal polymicrogyria 
(BFPP), a congenital brain malformation. The GPS point mutations C346S and 
W349S impair cleavage and block protein trafficking to plasma membrane
101
. 
However, whether hsCELSR2 is regulated by the self-proteolysis process in 
physiologic contexts remains to be clarified. 
A seven transmembrane helical region (7-TM) is located after the GAIN domain. Two 
conserved cysteines from the first and the second extracellular loop (C2439 and 
C2511) can form a disulfide bond that, stabilizing the extracellular structure might 
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ensure efficient ligand binding or conformational changes 
102
, as it has already been 
shown for the gonadotropin-releasing hormone receptor, a class A GPCR 
103
. 
However, the TM bundle of CESLR2 is still orphan, undrugged and unexplored 
(IUPHAR/BPS). 
The intracellular part of CELSR2, that includes intracellular loop 1-3, serves as a 
docking point for downstream effectors in the cytoplasm. The intracellular loop 3 
contains about 20 amino acids and provide structural flexibility. Interestingly, 
CELSR2 has an arginine (Arg2413) in the first intracellular loop that is not shared by 
other family members. The latter, indeed, at the same position have a histidine 
(His2573). Site directed mutagenesis experiments showed that the Arg2413 in 
CELSR2 and the His2573 in CELSR3 are responsible for the opposite roles of these 
two proteins in neuron growth regulation
104
, with CELSR2 enhancing and CELSR3 
inhibiting neurite growth. 
Finally, after the helix 7, CELSR2 has a C-tail of 304 amino acids enriched with Ser, 
Thr, Pro and acidic residues Glu and Asp. Moreover, CELSR2 has several predicted 
PEST regions (signal peptide for protein degradation) that may regulate receptor 
turnover in the cell
105
. 
The domain organization is strikingly conserved among CELSR2-like proteins in 
different species. The vertebrate genomes contain three homologs: CELSR1, CELSR2 
and CELSR3 whereas Drosophila melanogaster and Caenorhabditis elegans genomes 
contain one ortholog of CELSR2, the proteins flamingo/starry night (fmi/stan) and 
Flamingo (fmi-1), respectively. The extracellular domains show a high degree of 
similarity between species, whereas the intracellular domains vary in length and are 
generally not conserved
106
 (Fig. 29).  
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Figure 28. The conserved structural core of the extracellular regions of adhesion GPCRs, 
as revealed by the X-ray structure analysis of latrophilin. The GAIN domain, that is highly 
conserved among the 33 mammalian adhesion GPCRs, folds in an α-helical and a β-sandwich 
subdomain. The auto proteolytic processing occurs in a tight turn between the last two strands 
of the domain. On the contrary, the GAIN α-helical subdomain of latrophilin interacts with a 
HormR domain. This interdomain contact, and/or a direct interaction with the transmembrane 
helical bundle, may allow the GAIN domain to auto-inhibit transmembrane signaling to 
heterotrimeric G proteins or other factors inside the cell. After cleavage, the cleaved fragment 
appears firmly anchored within the GAIN domain by extensive backbone hydrogen bonds and 
hydrophobic interactions. Image adapted from The EMBO Journal (2012) 31, 1334–1335. 
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Figure 29. Protein domain organization of CELSR2. CELSR2 ectodomain contains 
9 Cadherin repeats, 7 EGF-like domains, 2 Laminin G-like domains, one Laminin-
EGF-like domain and one hormone receptor motif (HormR). The ECD is followed by 
the canonical GPCR transmembrane assemblement with 7 transmembrane (TM) 
helices. ECD and the first transmembrane are joint together by a GPCR self-
proteolysis site (GPS). The protein domain organization of Drosophila Flamingo and 
C.elegans FM-1 are shown for comparison. Image adapted from Development 137, 
3663-3673 (2010). 
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CELSR2 cellular functions 
 
CELSR2 is widely expressed in nervous system and its expression is spatially and 
temporally regulated
107,108
. It is mainly localized in dendrites and axons of different 
types of embryonic and post-natal neurons
109
. It is also expressed in non-neuronal 
epithelia, such as kidney, lungs, skin, endothelial cells, gastrointestinal and 
reproductive systems. Phenotypic analysis of CELSR2 mutants showed its 
involvement in both epithelial and neuronal morphogenesis.  
There are several evidences of the role of CELSR2 in cilia development and 
organization. In mouse nervous tissue cells, CELSR2 controls function of cilia that, 
normally, beat in a coordinated manner to facilitate circulation of the cerebrospinal 
fluid. Indeed, CELSR2 mutants affect this process causing defective beats at 
individual cell level
110,111
 (Fig. 30 a). Mice with homozygous null mutations in 
CELSR2 gene develop hydrocephalus with accumulation of cerebrospinal fluid within 
the brain, due to decreased numbers of cilia that are also short and abnormally 
oriented
110
. CELSR2 regulates ciliogenesis via Planar cell polarity
112
, the signalling 
pathway involved in the orientation of cells and cellular structures along an axis within 
the plane of an epithelial surface. Indeed, in CELSR2 mutant cells, the membrane 
localization of VANGL2 and FZD3, two key regulators of planar cell polarity (PCP), 
is disrupted
112
. The role of CELSR2 in human ciliopathies was recently emphasized 
with the demonstration that mutated CELSR2 is implicated in Joubert syndrome 
(JS)
113
. This genetic disease has a prevalence of 1-9/100,000 and it is characterized by 
central nervous system malformations with neurological features (ataxia, cognitive 
impairment, abnormal eye and tongue movements) and multisystem organ 
involvement (fibrocystic kidney and liver disease, retinal dystrophy and 
polydattilia)
111
. Consequently, defects of CELSR2 function might be associated also to 
other pathological conditions characterized by cilia abnormalities such as cystic 
pathology in liver, kidney and pancreas.  
CELSR2 is also involved in neuronal migration. In zebrafish embryos, loss of function 
of CELSR2 results in migration defects of the neurons controlling the muscles of 
facial expression also known as facial brachiomotor neurons (FBMN)
114
. Another 
evidence of CELSR2 involvement in neuronal migration is given by CELSR2 mutant 
mice, where the directionality of the neuron migration is compromised
115
. 
Furthermore, in cells from Drosophila embryos the C-terminal truncated form of 
Flamingo (fmi, homolog of CELSR2) affects cell cohesion that primarily leads to the 
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in vivo cell movement defects
116
. Less is known about CELSR2 molecular function in 
cell migration. However, the phenotype of CELSR2 mutants is similar to that of FZD3 
mutants and other PCP related genes also implicated in FBMN migration
117
.  
Other structure-phenotype analysis showed that CELSR2 plays an important role also 
in dendrite development and axon guidance, from Drosophila to mammals.  
In Drosophila, fmi mutants affect both the dendritic morphogenesis and the 
competition between dendrites of homologous neurons in embryonic peripheral 
nervous system (PNS)
118
 (Fig. 30 b). Structure-function analysis showed that the 
expression of a fmi truncated form lacking the entire cadherin repeat sequence, rescues 
overgrowth of branches in fmi-mutants in the early stage of dendritic development. In 
fmi-mutants, another phenotype observed in the later stage, is the branches overlapping 
that is reproduced by the overexpression of the ECD truncated form of CELSR2 in the 
wild-type background
119
. These studies suggest that fmi could play two different roles 
during dentritic development: act as a receptor for an unknown ligand to limit branch 
elongation in the initial phase and establish homophilic interactions to elicit avoidance 
between dendritic terminals in the terminal phase. 
CELSR2 regulation of dendritic maintenance and growth exists also in mammals. 
Normally, dendrites are highly dynamic and undergo rapid and continuous extensions 
and retractions
93
. In cultures of murine brain slices, loss of function of CELSR2 by 
siRNA causes severe simplification of dendritic arbores probably due to a more 
frequent dendritic retraction (Fig. 30 c). Indeed, the siRNA induced phenotype is 
rescued by co-expressing a siRNA resistant form of CELSR2, containing only the 
cadherin domain in the ECD, that is not able to promote elongation when expressed by 
itself 
92
. Finally, CELSR2 cadherin domain is necessary for the rescue of the retraction 
phenotype and homophilic CELSR2-CELSR2 interactions might have a central role in 
maintaining dendritic arbores. 
CELSR2 plays a pivotal role also in axon growth. Fmi gene mutations are lethal in 
Droshophila embryos and the mutant embryos showed local disconnection of 
longitudinal axon tracts in the central nervous system
106
 (Fig. 30 d). CELSR2 might 
regulate axon development by PCP-independent pathways since mutants of PCP genes 
do not display the axon phenotype seen in fmi mutant neurons
106
. Axonal defects and 
correlated lethality can be rescued by fmi expression in the nervous system of the 
mutants indicating that the role of this receptor is essential for viability.  
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Finally, CELSR2 regulates cellular functions such as cell adhesion, migration, polarity 
and guidance, which are all highly relevant to tumour cell biology. Nevertheless many 
questions remain unanswered, such as how CELSR2 is activated, who are CELSR2 
endogenous ligands and what signal they transduce and whether CELSR2 can be 
coupled to G proteins.  
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Figure 30. CELSR2/Flamingo roles in physiological processes. (a) During the first 
postnatal week, cilia basal body (green arrowheads) point in different directions. In the adult, 
in response to planar cell polarity signals, they rotate and adopt a more uniform orientation 
that enables cilia to beat in a coordinated manner and generate a directed fluid flow. In 
CELSR2 mutant cells, basal bodies exhibit divergent orientation and fail to generate a directed 
fluid flow. (b) In Drosophila, peripheral neuron dendrites avoid dendrites of homologous 
neurons in normal conditions. In fmi mutants, on the contrary, dendrites establish competitive 
interactions. (c) In mouse neuronal cultures, knocking down CELSR2 suppresses neurite 
growth. (d) In flamingo mutants, axons make directional errors and innervate inappropriate 
targets. 
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CELSR2 molecular partners 
 
There are several lines of evidence, both in Drosophila and mammals, of the CELSR2 
involvement in the planar cell polarity signalling, that is the polarity axis that 
organizes cells in the plane of the tissue. It seems that fmi/CELSR2 works together 
with PCP genes in development processes that require cell polarity, including hair cell 
orientation, convergence and extension and neuronal migration. 
CELSR2 ortholog fmi has been found to functionally interact with key PCP proteins, 
including the 7-TM receptor Frizzled, tetraspanin Van Gogh, Dishevelled, Prickle and 
probably other less clearly identified members. Also in mammals, CELSR2 works 
together with Frizzled3 and Vangl-2
120
. In the context of PCP signalling pathway, 
CELSR2 may regulate the C-JUN N-terminal kinase (JNK) pathway, that is known to 
be activated by PCP in multiple organs
121
. Phosphorylation of c-Jun during pancreatic 
development relies on CELSR2 activity, indeed, CELSR2 KO mice embryos have a 
downregulation of phospho-Jun in pancreatic buds
122
. 
In contrast, fmi/CELSR2 may act by PCP-indipendent pathway in other kind of 
physiologic processes such as dendritogenesis and axon advance. 
In mammals, CELSR2 role in dendritogenesis has been proved to be dependent on 
homophilic interactions of CELSR2 cadherin domains. In this way, CELSR2 may 
activate Phospholipase C to produce inositol-3-phosphate that is responsible of a 
calcium release from internal stores
90
. These evidences suggest that CELSR2 have a 
GPCR activity, however, it would be necessary to carry out biochemical analysis to 
identify relevant G proteins. Moreover, several lines of evidences suggest that 
CELSR2 is linked to calcium/calmodulin-dependent protein kinase II (CaMKII). 
Pharmacological inhibition experiments, for example, revealed that CaMKII mediate 
CELSR2 cadherin domain effects on neurite growth
93
.  
Also in Drosophila, fmi mediates homophilic interactions in neuro epithelial cells to 
regulate axon guidance. In Drosophila, several transmembrane molecules have been 
shown to regulate axon guidance and among these, the transmembrane receptor 
Golden Goal (gogo) have phenotypic similarities and genetically interacts with fmi 
123
. 
gogo and fmi can mutually influence their localization and this suggests that they are 
molecular partners. Moreover, fmi seems to trigger intracellular signaling via gogo 
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since the synergistic effect of gogo and fmi overexpression in recovering  phenotype of 
fmi mutant neurons depends on Gogo cytoplasmic domain
123
.  
Finally, to date, less is known about the signaling events triggered by CELSR2 
activation or inactivation. One potential cause is the lack of efficient in vitro research 
tools, such as selective compounds that specifically activate or inactivate CELSR2. 
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Spatiotemporal expression profiles of CELSR proteins in zebrafish 
 
Recently, zebrafish (Danio rerio) has proven to be a useful model to study adhesion 
GPCRs from a functional prospective, especially in development context. The utility 
of this model has been further underlined by a genomic study that identified the 
adhesion GPCRs encoded by the zebrafish genome. Moreover, in this study the 
expression profiles of each adhesion GPCRs identified in zebrafish was provided by 
using high-throughput quantitative real-time PCR in a collection of 12 developmental 
time-points and 10 adult tissues. The following tissues were selected to represent the 
major organ systems: brain, eye, heart, intestine, kidney, liver, skeletal muscle, skin, 
ovaries and testes. On the contrary, the developmental time-points that were chosen to 
represent major milestones are the following: 1 hour post-fertilization (hpf; cleavage 
period, ~4 cells), 3 hpf (blastula period; ~1000 cells), 5.3 hpf (early gastrulation), 10 
hpf (late gastrulation, early segmentation), 14 hpf (segmentation), 24 hpf (most organ 
systems have formed), 3 days post-fertilization (dpf,  larvae have hatched from 
chorions), 5 dpf (swimming), 7 dpf, 11 dpf, 14 dpf, and 21 dpf (juvenile stages defined 
by active hunting and rapid body growth) 
124
.  
Interestingly, the study revealed that there are at least 59 adhesion GPCRs in zebrafish 
representing 24 of the 33 human aGPCRs. Moreover, zebrafish adhesion GPCRs have 
similar expression profiles as their homologs in mouse, rat and human. CELSR1 and 
CELSR2 are  highly expressed during gastrulation and segmentation stages and then 
expressed at lower levels during later development and in adult tissues. In particular, 
they are significantly enriched between 10 and 15 hours post fertilization, in contrast, 
CELSR3 is lowly expressed until 3 dpf, and then highly enriched in the brain, eye, and 
skeletal muscle in adults. 
Phylogenetic analysis suggest that zebrafish aGPCRs cluster closely with their 
mammalian homologs and are organized in the same nine groups as previously 
described for the human aGPCR repertoire. Also structure prediction studies show that 
most zebrafish aGPCRs share relevant protein domains found in the N-termini of their 
mammalian counterparts. Importantly, the high level of homology between zebrafish 
and human adhesion GPCRs found in this study is consistent with global 
characteristics of the zebrafish genome relative to the human genome. For example, 
71.4% of all human genes have at least one ortholog in zebrafish, which is consistent 
with the data that 72.7% of human aGPCRs have at least one zebrafish ortholog. Thus, 
studying adhesion GPCRs by using zebrafish as model could have important 
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implications also for understanding some functional aspects of adhesion GPCRs in 
humans. 
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Inapplicability of traditional GPCR screening technologies to CELSR2 
deorphanization 
 
In the last decades, several GPCR assays have been designed to identify novel drug 
candidates. Historically, radio ligand binding assays have been used to screen GPCRs 
for lead compounds. This assay is also known as “radio-ligand displacement assay” 
since compounds are characterized for their ability to displace the binding of a radio 
labelled ligand to the target
125
. Although this assay has been widely used to identify 
new ligands of GPCRs, it is not useful for the deorphanization of CELSR2 as well as 
of the other orphan GPCRs. Indeed, the lack of information about orphan GPCR 
endogenous ligands and the absence of any traceable radioactive ligand binding to 
CELSR2 makes this assay inapplicable to the deorphanization of this receptor. 
New binding assays, based on the fluorescence resonance energy transfer (FRET) 
technology, and “functional assays” have been developed to study both the compound 
activity and its effect as potential novel drug candidate. Originally, functional assays 
were G-protein dependent since they were based on the measurement of G-protein-
mediated second messenger generation. For example, Guanine nucleotide binding 
assay measures an early event after GPCR activation that is the release of GDP from 
the G-protein and the binding of GTP. On the other hand, a functional assay that 
measures a downstream effect of GPCR activation is the cAMP assay. This assay, 
indeed, is sensitive to variations in cAMP intracellular levels. Taking advantage of the 
new insights into GPCR signal transduction, many G-protein-independent assays have 
been developed to provide additional information on the functional selectivity of the 
candidate compounds. Among these assays, receptor internalization assay allows to 
visualize GPCR internalization by labelling GPCR with fluorescent proteins (GFP or 
RFP). When internalized, the tagged-GPCR forms intracellular spots that are analysed 
by a detector
126
. This assay was proved to be useful for GPCR deorphanization. 
Indeed, with the internalization assay it has been showed that unsaturated long-chain 
free fatty acids activate the so far, orphan receptor GPR120
127
. 
However, most of the functional assays are not useful to identify ligands of orphan 
receptors like CELSR2. Indeed, they rely on monitoring changes at the second 
messenger level. Unfortunately, to date, the knowledge about orphan GPCRs role in 
the transmission of signal pathways is limited. 
.  
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Deorphanization strategies 
 
In the last decades, the rate of GPCR deorphanization decreased drastically because of 
the inapplicability of the traditional screening assays. 
Some attempts to develop appropriate assays for GPCRs deorphanization led to 
alternative functional assays. For example, an alternative calcium assay approach takes 
advantage of the propriety of promiscuous Gα subunits to enforce Gαi, Gαs coupled-
receptor to signal via PLC-IP3-Ca
2+
. Overexpression of promiscuous G-proteins in 
reporter cells, containing the receptor and a calcium sensitive probe, allows to perform 
the assay also without preventive knowledge of G-protein coupling conditions or 
signalling pathways
128
. Recently, an elegant way of measuring GPCR activation by 
using β-arrestin translocation has been developed. Before starting screening, this 
system ensures, in a ligand independent way, that the receptor can recruit arrestin 
proteins after stimulation. This approach uses a constitutively active kinase (GRK2) to 
phosphorylate the receptor and initiate GPCR-β-arrestin interaction129. Another way to 
study signalling proprieties of orphan GPCRs with unknown G-protein coupling is to 
overexpress them in a cell line and then measure activation of a specific signalling 
pathway. The overexpression, indeed, cause a constitutive receptor activation that 
might be successful to identify some intracellular signalling characteristics
130
. This 
method has been used to identify GPR101 activities in the central nervous system via 
modulation of cAMP levels
130
. However, the successful application of these methods 
depends on sufficient orphan receptor expression. It is well known that the expression 
and membrane translocation of some GPCRs, in reporter cell lines such as Hek293 or 
COS-1, can fail because of a lack of a specific protein maturation machinery. Other 
limitations are due to a different pharmacology and/or biological role of certain 
receptors. Some of the orphan receptors may simply have ligand-independent 
functions. Several examples include GABAB, GPR50 and the constitutively active 
receptors. 
To avoid these difficulties, different in silico strategies are being attempted to identify 
candidate endogenous ligands. Bioinformatics provides tools to predict cognate 
ligands based on sequence homology. For example, the orphan receptor GPR105 
(known as P2Y14) has been deorphanized in virtue of its high level of homology with 
other purinergic receptors. Indeed, the orphan receptor was screened against a library 
containing nucleotide di- and triphosphate conjugates to identify UDP-glucose as 
ligand. Also the deorphanization of EDG-3 and EDG-5 receptors was successfully 
81 
 
conduced on the basis of a sequence homology analysis that showed an high level of 
homology with EDG-1, the receptor binding sphingosine-1-phosphate (SP-1)
131
. 
Moreover, the deposition of high resolution X-ray and NMR structures represents an 
opportunity to give a boost to structure-based design (SBDD), an effective tool to 
design potential agonists or antagonists. SBDD in conjunction with computer 
modelling allowed the identification of allosteric modulators and agonists of the 
proton receptor GPR68
132
. Notwithstanding, the specificity that some ligands have 
revealed for GPCRs has mined a full confidence in such strategy. CD97 and EMR2 
receptors, for example, share 97% sequence identity while, in contrast, their ligand 
CD55 binds with high affinity only to CD97 and not to EMR2. On the other hand, 
alkyl-imidazoles function as dual Histamine H3/H4 receptors, while these receptors 
share very little sequence identity. These examples suggest the “similarity” based 
approaches must be taken with caution
133,134
.  
Thus, the development of a universal (valid for all the remaining OrphG), improved 
(designed to overcome problems nowadays faced with traditional approaches) and 
sensitive (needing low amount of expressed/purified OrphG) platform for OrphG 
deorphanization is urgently needed. 
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RESULTS   
Development of a specific PC-platform to use for the identification of 
CELSR2 modulators 
 
In CELSR2 two conserved cysteines from the first and the second extracellular loop 
(C2439 and C2511) can form a disulfide bond that, stabilizing the extracellular 
structure might ensure efficient ligand binding or conformational changes
102
, as has 
already been shown for the gonadotropin-releasing hormone receptor, a class A 
GPCR
103
. Thus, we supported the idea that CELSR2 TM-bundle can potentially bind 
ligands to modulate receptor activity.  
We attempted to deorphanize the TM bundle of CELSR2 by using the novel PC-
platform recently ideated in our research group. As already described, PC-Platform 
identifies new ligands in virtue of their ability to act as pharmacological chaperones 
(Fig. 31). Therefore, the target receptor must be as first made misfolded in a way to 
trap it intracellularly so that a library of molecules and compounds can be evaluated 
for their ability to interact with the target protein and correct its folding and cellular 
localization.  
To generate misfolded versions of the CELSR2 TMD, we created as first, two mutant 
receptors fully or partially deleted of their extracellular domain. The CELSR2 ECD 
consists of 2350 aa: the juxta-membrane region (containing the EGF-laminin G and 
the Hormone Receptor domains) and the more distal region containing EGF-like, 
Laminin G and a string of tandemly repeated cadherin domains. We generated a cDNA 
coding for CELSR2(1917-2923), missing only the distal region, and CELSR2(2358-
2617) a CELSR2 variant missing the entire ECD (Fig. 32).  
We also tried to affect folding impairing the proteolytic processing of CELSR2 at the 
GPS. Several lines of evidences suggest that mutations in the GAIN domain and more 
specifically of the GPS consensus sequence might lead to protein folding defects, 
which would in turn impair the receptor trafficking. Hence, we introduced the single 
point mutations, H2355S and T2357G in the GPS consensus sequence of 
CELSR2(1917-2923) and CELSR2(2358-2617) to generate CELSR2(1917-
2923)ΔGPS and CELSR2(2358-2617)ΔGPS (Fig. 32).  
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In third line, to increase the chance of obtaining a misfolded variant of CELSR2, we 
decided to replace its tail with the carboxyl-terminal tail of Frizzled-4 L501fsz533. 
This latter is a mutant of the class F GPCR receptor Frizzled-4 which is responsible in 
vivo for the Familial Exudative Vitreoretinopathy (FEVR), a pathology of the retina. 
This amino-acidic sequence, henceforth referred to as FEVR, is a disposable module 
inducing misfolding and aggregation. The FEVR tail causes the trapping of the 
misfolded receptor in the ER, in contrast to the wt receptor that is localized at steady 
state on the PM of the cells. We have already shown that when the FEVR tail is 
appended to the C-terminal tail of other transmembrane proteins (even Type I 
transmembrane protein like human CD8 and the viral VSV-G) it induces misfolding, 
aggregation and trapping of the chimeric proteins in the ER
65
. We decided to append 
the FEVR tail at the C-terminal of CELSR2(2358-2617), CELSR2(1917-2923)ΔGPS 
and CELSR2(2358-2617)ΔGPS to obtain the following mutants: CELSR2(1917-
2617)FEVR, CELSR2(1917-2617)ΔGPS_FEVR and CELSR22(2358-
2617)ΔGPS_FEVR (Fig. 32). 
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Figure  31. Schematic representation of the PC-platform showing wt receptors 
localized at PM and mutant receptors being  trapped in the ER. Molecules are 
screened for their ability to interact with the mutant receptor and correct its 
folding and localization. 
Wt targets localize on 
Plasma Membrane 
Ligand binding rescues folding and 
localization of mutant targets to Plasma 
Membrane 
Mutant targets localize 
intracellularly trapped in the 
Endoplasmic Reticulum 
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Figure 32. Schematic representation of CELSR2 wt and CELSR2 mutants 
generated to obtain a misfolded version of this receptor.  
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CELSR2 mutants expression in mammalian cells 
 
CELSR2 constructs were expressed in mammalian cells (Hek293 and HUH7.5 cells). 
Their cellular localization was analyzed by using immunofluorescence and western 
blot analysis, 48 hours post transfection. Hek293 cells were used for Western Blot 
analysis for the easiness of their transfectability. HUH7.5 cells, on the other hand, 
were used to perform immunofluorescence analysis, since for their flat shape suit 
better immunofluorescence study of PM-localized proteins.  
As shown by the immunofluorescence data, CELSR2(1917-2923) is correctly 
localized on Plasma Membrane (PM). In this case, the lack of the EGF-like, Laminin 
G and Cadherin domains did not affect the intracellular protein trafficking. Moreover, 
the auto proteolytic processing gives rise to the expected cleaved protein at 48KDa 
(fig. 33 a, d).  
Mutations affecting CELSR2 folding should trap CELSR2 mutants in the Endoplasmic 
Reticulum (ER). CELSR2(1917-2923)ΔGPS presenting the two points mutations 
abolishing autocatalytic cleavage activity appears, as expected, mainly as full length 
protein of 109 KDa. However, this un-cleaved CELSR2 variant is still correctly 
localized at PM (Fig. 33 a, d). In our cellular system, the receptor cleavage is thus not 
essential for folding and trafficking to PM. Contrary to our expectations, also the 
membrane localization of the CELSR2(1917-2617)FEVR variant was not affected by 
the presence of the FEVR tail. Also for this construct, the mutant is normally cleaved 
and visible as a band at 48 KDa (Fig. 33 b, d). Similarly, the membrane localization of 
CELSR2(1917-2617)ΔGPS_FEVR is only partially affected but, as expected the 
mutant protein is resistant to the autoproteolytic cleavage (full length at 81 KDa) (Fig. 
33 b, d). Finally, as predicted, the lack of the entire extracellular domain causes 
misfolding of CELSR2(2358-2617)ΔGPS and CELSR2(2358-2617)ΔGPS_FEVR 
variants. Indeed, the two mutants  are uncleaved (full lengths at 61 KDa and 32.8 KDa 
respectively) unprocessed and totally insoluble in non-reducing conditions. Moreover, 
the IF data show that they are totally trapped in the ER (Fig. 33 c, d).  
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We thus obtained two CELSR2 variants misfolded and trapped in the ER. They are 
designed as CELSR2(2358-2617)ΔGPS and CELSR2(2358-2617)ΔGPS_FEVR and 
are characterized by the deletion of the extracellular domain.  
Then we proved that CELSR2(2358-2617)ΔGPS and CELSR2(2358-
2617)ΔGPS_FEVR folding and plasma membrane localization could be rescued. We 
attempted to rescue the folding of the CELSR2 misfolded variants by co-expressing in 
trans their extracellular domains. We generated constructs expressing both the string 
of CELSR2 cadherin domains and the EGF-like-laminin G domains. We proved that 
when CELSR2(2358-2617)ΔGPS and CELSR2(2358-2617)ΔGPS_FEVR constructs 
were co-expressed with the corresponding isolated CELSR2(Cadherin domain), the 
plasma membrane localization of these constructs was rescued in 80% and 60% of the 
cell population, respectively (Fig. 34 a, b, c). In contrast, CELSR2 mutants, when co-
expressed with the isolated CELSR2(EGF-like Laminin G domains), are still 
misfolded and trapped in the ER (Fig. 34 a, b). 
Finally, we decided to use extracellular deletion mutants of CELSR2 to generate the 
biological platform for the screening campaign. The construct CELSR2 (Cadherin 
domain) was used as PC-Platform positive control.  
Figure 33. The deletion of the whole extracellular domain of CELSR2 causes the 
misfolding and trapping of the protein in the ER. (a) Hek293 and HUH7.5 cells were 
transfected with vectors coding CELSR2 mutants. Cellular localization of each mutants was 
analyzed by Western Blot and by immunofluorescence (a,b,c). Western Blot results are shown 
on the left side. 48 h after transfection Hek293 cells were lysed in TritonX-100.  Proteins were 
denatured in SDS at 37 °C for 20 min, and run on either reducing or non-reducing SDS-PAGE 
and processed for W.B. Filters were decorated with an anti-V5 antibody to reveal CELSR2 
(only relevant part of the gels are shown). GPS Point mutations abolish cleavage activity. Full 
length and cleaved proteins are shown. Deletion of the whole extracellular domain makes the 
proteins insoluble in non-reducing conditions. For immunofluorescence analysis, CELSR2 
mutants were expressed in HUH7.5 cells (results are showed on the right side) 
immunofluorescence of permeabilized (intracellular) cells showing PM and ER localization of 
CELSR2 mutants (red). Deletion of the full extracellular domain causes the trapping of the 
proteins in the ER. (d) Percentage of PM and ER localization of CELSR2 mutants 48 h after 
transfection in Hek293 cells (n=3 independent experiments, co-localization was calculated in 
30 cells for each replicate). 
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Figure 34. Rescue of CELSR2(2358-2923)ΔGPS and CELSR2(2358-2617)ΔGPS_FEVR 
upon co-transfection with CELSR2 (Cadherin domain) in HUH7.5 cells. (a) 
Immunofluorescence of permeabilized cells showing ER localization of CELSR2 mutants and 
rescue of CELSR2 mutants localization at PM after co-transfection with the 
CELSR2(Cadherin domain). CELSR2 (EGF_Laminin G domain) failed in rescuing CELSR2 
mutants PM localization. (b) Percentage of PM and ER localization of CELSR2(2358-
2923)ΔGPS and CELSR2(2358-2617)ΔGPS_FEVR before and after co-transfection with 
CELSR2 (Cadherin domain) and CELSR2 (EGF_Laminin G domain) (n=3 independent 
experiments, co-localization was calculated in 30 cells for each replicate). (c) W.B analysis of 
CELSR2(Cadherin domain) expression in Hek293 cells 48h after transfection. 
a 
b 
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Generation of CELSR2 endogenous metabolite library  
 
We decided to create a metabolite library by using Zebrafish as biomass. Indeed, there 
is an high level of homology between aGPCRs found in human and zebrafish genome. 
Expression profiles of zebrafish adhesion GPCRs during development
124
 shows 
CELSR2 enrichment during gastrulation and segmentation stages and specifically 
between 10 and 15 hours post fertilization. For this reason, we decided to collect 
Zebrafish eggs (more then 100.000) at 15 hours post fertilization and then, we 
performed a three phase extraction of the metabolites. We used the organic solvents N-
hexane, butanol and ethyl acetate to obtain hexane (25 mg), ethyl acetate (7 mg),  
butanol (26 mg) and residual aqueous fractions (242 mg) respectively. Ethyl acetate, 
butanol and aqueous fractions, were re-suspended in dimethyl sulfoxide (DMSO) at a 
concentration of 10 mg/ml. Hexane fraction was insoluble in DMSO (Fig. 35). 
Fractions obtained were screened for pharmacological chaperone efficiency.  
 
  
Figure 35. Generation of a metabolite library to be screened by using PC-
platform. Zebrafish eggs were used as biomass to obtain a metabolite library. After a 
three phase metabolite extraction, fractions obtained were screened for 
pharmacological chaperone efficiency on Hek293 cells expressing CELSR2(2358-
2923)ΔGPS and CELSR2(2358-2617)ΔGPS_FEVR. 
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Rescue of ER-trapped CELSR2 mutants as readout to identify CELSR2 
modulators 
 
Hek293 cells were transfected with vectors coding for CELSR2(2358-2617)ΔGPS and 
CELSR2(2358-2617)ΔGPS_FEVR mutants; 4 hours after transfection cells were 
treated with ethyl acetate, butanol or aqueous fractions at 3 different final 
concentrations: 100 μM, 10 μM and 1 μM. The dilutions were performed in 10% FBS 
supplemented DMEM and after centrifugation at 112 RCF, fractions were divided in 
two parts: insoluble and soluble (named fraction 1 and 2 respectively). 72 hours after 
transfection, chaperone activity was assayed by measuring the recovery of CELSR2 
mutants localization at the PM. We used DMSO as negative control. Soluble ethyl 
acetate fraction at the concentration of 100μM rescued CELSR2(2358-2923)ΔGPS 
localization at the PM in the 40% of the cell population (Fig. 36). Also insoluble ethyl 
acetate and butanol fractions (100 μM) rescued CELSR2(2358-2923)ΔGPS at the PM 
in the 20% of the cell population (Fig. 36). On the contrary, butanol and aqueous 
fractions either at 100 μM or 10 μM were able to rescue CELSR2(2358-
2617)ΔGPS_FEVR at PM in than the 20% of the cell population (Fig. 37).  
We obtained different fractions that are active on rescuing the folding of the two 
CELSR2 variants. Moreover, the mutations characterizing these constructs induce 
deep changes in the protein conformation so that their folding can be modulated by 
compounds with different chemical properties. 
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Figure 36. Rescue of CELSR2(2358-2923)ΔGPS PM localization as biological platform 
toward the identification of CELSR2-wt modulators. Bar graphs representation of metabolite 
fractions that  rescue of CELSR2(2358-2923)ΔGPS PM localization (n = 3, ten random fields 
containing at least 50 cells counted for each replicate; s.d. are indicated). Each fraction was 
tested at three final concentrations: 100 μM (a), 10 μM (b) and 1 μM (c). The fraction dilutions 
were performed in 10% FBS supplemented DMEM and after centrifugation at 112 RCF, each 
fraction was divided in two parts: insoluble and soluble (fraction 1 and 2, respectively). 
a
 
 a 
 a 
b
 
 a 
 a 
c
 
 a 
 a 
10 μM 
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Figure 37. Rescue of CELSR2(2358-2923)ΔGPS_FEVR PM localization as biological 
platform toward the identification of CELSR2-wt modulators. Bar graphs of metabolite 
fractions rescue of CELSR2(2358-2923)ΔGPS_FEVR PM localization (n = 3, ten random fields 
containing at least 50 cells counted for each replicate; s.d. are indicated). Each fraction was 
tested at three final concentration: 100 μM (a), 10 μM (b) and 1 μM (c). The fraction dilutions 
were performed in 10% FBS supplemented DMEM and after centrifugation at 112 RCF, each 
fraction was divided in two parts: insoluble and soluble (fraction 1 and 2, respectively). 
c
 
 a 
 a 
a
 
 a 
 a 
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Three molecules from Ethyl acetate fraction act as CELSR2 modulators 
 
We collected information about the chemical composition of the most active fraction 
ethyl acetate. We used Direct Infusion Fourier Transform-ion cyclotron resonance 
mass spectrometry (DI-FT-ICR-MS), which is characterized by unmatched ultra-high 
mass accuracy and resolution. FT-ICR analysis revealed that this fraction contained 
carotenoids, prostaglandinE2 (PGE2), bile acids, and cholesterol (Supplementary Fig. 
1, Fig. 2, Fig. 3 and Fig. 4). For this reason, we decided to evaluate the 
pharmacological chaperone efficiency of these molecules. We transfected Hek293 
cells with CELSR2(22358-2923)ΔGPS and 4 hours after transfection we treated them 
with the above mentioned compounds. Chaperone activity was assayed by measuring 
the recovery of the CELSR2 mutant localization at the PM, 72 hours after transfection. 
Among the tested candidates, β-carotene rescued CELSR2(2358-2617)ΔGPS PM 
localization with an efficiency higher than 40%. In contrast, Taurocholic acid failed in 
rescuing CELSR2(2358-2617)ΔGPS PM localization. PGE2 and cholesterol had a 
similar effect with a maximum of 15% of cells with the mutant protein at PM. 
However, PGE2 at the highest concentration was toxic for cells (Fig. 38). We showed 
that the EC50 of β-carotene was ~ 1 μM, on the contrary PGE2 and cholesterol EC50 
was ~ 2 μM and 1 μM, respectively (Fig. 38).  
We also proved that β-carotene, PGE2 and cholesterol did not rescue either Fz4-FEVR 
or the mutant CFTRΔF508, indicating that the molecules did not act as promiscuous 
molecular chaperones (Fig. 39).  
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Figure 38. Screening of compounds composing the ethyl acetate fraction for rescuing  
CELSR2(2358-2923)ΔGPS PM localization. Bar graphs of β-carotene, PGE2 and 
cholesterol  rescue of CELSR2(2358-2923)ΔGPS PM localization (n = 3, ten random fields 
containing at least 50 cells counted for each replicate; s.d. are indicated). In a preliminary 
experiment (a) compounds composing the ethyl acetate fraction were tested at three final 
concentrations: 30, 15 and 7,5 μM. Taurocholic acid failed in rescuing CELSR2 mutant 
localization and was excluded from further tests. On the contrary, β-carotene (b), PGE2 (c) 
and cholesterol (d) were tested in a wider range of concentrations (30 μM-0,4 μM). 
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 a 
 a 
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 c
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Figure 39. β-carotene, PGE2 and cholesterol specifically rescue CELSR2(2358-
2923)ΔGPS PM localization. β-carotene, PGE2 and cholesterol failed in rescuing the 
PM localization of the mutants CFTR-ΔF  and Fz4-FEVR. Intracellular localization 
of GFP tagged CFTR-ΔF (ER, on the left) and HA-tagged Fz4-FEVR (ER, in the 
middle) transiently transfected in Hek293 cells after treatment with (15 μM β-
carotene, 15 μM PGE2 and 15 μM cholesterol for 48 hours) or with vehicle alone. 
The right column shows the effect of the compounds on cells expressing 
CELSR2(2358-2923)ΔGPS. 
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Binding site prediction 
 
According to our binding site prediction, cholesterol allocates at the interface between 
the ICL1 and the juxta-membrane region of TM2, TM3 and TM4 of CELSR2 (Fig. 40 
a). Cholesterol hydroxyl group forms ionic bonds with the amino group of Asp2414 or 
Arg2413 of the ICL1. The four linked hydrocarbon rings are located between the 
apolar residues Ala2417 and Leu2421 of the TM2 and the polar residues Trp2487 and 
Tyr2483 of TM4. The aliphatic chain protrudes in an apolar cavity formed by Ala2490 
of TM4 and by Leu2445 and Leu2449 of the TM3. According to our model, two 
molecules of cholesterol can be localized at the same binding site with their hydroxyl 
groups interacting with the hydrophilic region of the ICL1 and the four hydrocarbon 
rings with the aliphatic chain enclosed in the hydrophobic region formed by the 
transmembrane helices (Fig. 40 b).  
Similarly to cholesterol, β-carotene derivative compound retinoic acid, allocates at the 
interface between the ICL2 and the juxta-membrane region  of TM3, TM4 and TM5 of 
CELSR2 (Fig. 41). The carboxylic group forms an ionic interaction with Arg2469 of 
the ICL2. The aliphatic chain lodges in a cavity formed by apolar residues of the 
transmembrane helixes with the cyclohexenyl ring interacting with Phe2532 and 
Pro2529. 
According to our in silico model, the PGE2 carboxylic group interacts with Leu2519 
of the ECL1. The hydroxyl group at the C9 of the cyclopentanone ring interacts with 
the Ser2522 of the TM5. The two aliphatic side chains mostly contact apolar residues 
of the TM3, TM4 and TM5 (Fig. 42). 
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Figure 40. Cholesterol ligand binding site prediction. (a) Cholesterol 
allocates at the interface between the ICL1 and the juxta-membrane region of 
TM2, TM3 and TM4 of CELSR2. (b) Two molecules of cholesterol can be 
localized in the same binding site. 
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Figure 41. Retinoic acid ligand binding site prediction. The β-
carotene derivative compound retinoic acid, allocates at the 
interface between the ICL2 and the juxta-membrane region  of 
TM3, TM4 and TM5 of CELSR2. 
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Figure 42. PGE2 ligand binding site prediction. PGE2 is located 
at the interface between the ECL1 and the juxta-membrane region of 
the TM3, TM4 and TM5 of CELSR2. 
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DISCUSSION 
 
CELSR2 in an adhesion GPCR overexpressed in Glioblastoma. To date, ligands 
binding CELSR2 have not yet been identified, thus it is classified as an orphan GPCR. 
In the last decade, the deorphanization rate has drastically slowed down because of the 
inapplicability of the traditional ligand screening platforms. Indeed, these latter 
identify ligands in virtue of their ability to either displace reference ligands or to affect 
signaling pathway linked to the target. However, we do not have any information 
about reference ligands and signaling pathways of orphan GPCRs. Recently we have 
ideated a new screening platform (PC-platform) that allows to identify new ligands in 
virtue of their ability to act as pharmacological chaperones. Here, we applied the PC-
platform for CELSR2 deorphanization. We generated misfolded and ER-trapped 
versions of CELSR2 and then different metabolite fractions extracted from zebrafish 
eggs were screened for their ability to correct folding and localization of CELSR2 
variants. β-carotene, cholesterol and ProglandinE2, which belongs to the most active 
fraction ethyl acetate, were able to rescue CELSR2 mutant folding and localization. 
We identified the hypothetical binding site of these molecules on CELSR2. They do 
not target the canonical orthosteric binding site of CELSR2 but seem to occupy 
hydrophobic cavities at the interface between the TM bundle and the lipid bilayer. By 
interacting with these regions, they probably hinder the receptor protecting it from 
aggregation.  
The identification of cholesterol and PGE2 as putative allosteric modulators of 
CELSR2 is consistent with the recent theory about the existence of “orphan” allosteric 
sites for, until now, unappreciated endogenous modulators
135
. Indeed, there are several 
examples of endogenous substances that can act as allosteric modulators of GPCRs. 
These include a variety of ions, lipids, amino acids, peptides, and accessory proteins 
that display different degrees of receptor specific modulatory effects
135
. In particular, it 
has been widely proved the cholesterol modulatory role on the function and ligand-
binding properties of several G-protein-coupled receptors (GPCRs). Indeed, crystal 
structures of prototypical GPCRs such as the adenosine A2A receptor (A2AR) have 
confirmed that cholesterol finds stable binding sites at the receptor interface with the 
lipid bilayer
136
. Moreover, it has been proved that the cholesterol inside the receptor 
allosterically modulate A2AR-binding affinity 
136
. Substantial interest in the potential 
for cholesterol to directly interact with GPCRs gained further impetus upon the 
solution of a 2.8-Å structure of the β2-AR simultaneously bound to two molecules of 
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cholesterol, and the identification in this binding site of a cholesterol consensus motif 
(CCM)
137
. Moreover, cholesterol depletion has been shown to affect receptor 
signaling. Indeed in this condition, the extracellular signal-regulated kinases 1/2 
(ERK1/2) phosphorylation and c-Fos activation for the gonadotrophin-releasing 
hormone receptor are lost, but can be restored upon replenishment
138
. 
Interestingly, the increasing identification of lipids or inflammatory molecules as 
GPCRs allosteric modulators indicates that disease context plays an important role in 
the generation of putative endogenous GPCR modulators. In a disease context, the 
presence of receptor-specific endogenous modulators likely points to a need for 
particularly tight regulation of certain GPCRs. For example, the ability of cholesterol 
to influence GPCR biology could depend on cholesterol levels that can vary 
dramatically in disease
139
. Similarly, the increase of the inflammatory mediators as a 
consequence of inflammatory processes likely introduce a plethora of substances, 
among these PGE2, that could otherwise go undetected as potential allosteric 
modulators. It is possible that the study of inflammation represents fertile ground for 
further discoveries in GPCR allostery. 
Some experimental evidences showed that cholesterol is required for dendrite 
differentiation, that is the rate limiting step for glia-induced synaptogenesis
140
. 
Specifically, Goritz et al.
140
 showed that cholesterol enhances directly dendritic 
differentiation and that it is essential for continuous synaptogenesis. So far, however, it 
remained unclear how cholesterol enhances the formation and function of synapses. 
Interestingly, structure-phenotype analysis showed that CELSR2 plays an important 
role in dendrite development, from Drosophila to mammals
92
. Kimura et al.
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experimental evidences suggested that during Drosophila dendritic development, 
CELSR2 could act as a receptor for an unknown ligand to control branch elongation. 
Thus, according to our data, cholesterol binding on CELSR2 could regulate this 
process either by direct modulation of CELSR2 activity or by modulating receptor 
clustering. Such an effect has been showed for Glutamate receptors, that are other 
receptors involved in synaptogenesis, whose postsynaptic clusters are sensitive to the 
neuronal cholesterol content. The hypothesis of cholesterol as an allosteric modulator 
of CELSR2 is also supported by the identification of a specific amino acid residue in 
the cholesterol ligand binding site on CELSR2, that is responsible for the receptor 
function in enhancing dendritic growth, as showed by site directed mutagenesis 
experiments
104
. This residue, the Arg2413, is localized in the first intracellular loop of 
CELSR2 and can form an ionic interaction with the cholesterol hydroxyl group.  
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Similarly, retinoic acid as potential allosteric modulator of CELSR2 could play an 
important role in neuronal differentiation. Indeed, it has been widely proved the 
involvement in the neuronal development either of CELSR2 
113
 and retinoic acid 
141
. 
Moreover, it has been shown that in an in vitro model of the CNS differentiation 
process, the retinoic acid requires the presence of ciliary proteins such as Meckelin and 
Jouberin to induce the neural differentiation of mouse embryonic stem cells
142
. 
Interestingly, CELSR2 has been proved to regulate ciligionesis and its role in human 
ciliopathies was recently emphasized with the demonstration that mutated CELSR2 is 
implicated in Joubert syndrome
113
. Thus, CELSR2 function as a ciliary protein could 
play an important role in retinoic acid-dependent neuronal differentiation.  
ProstagladinE2 has been shown to play an important role in physiological processes 
such as cell migration
143
. These processes are involved in gastrulation movements and 
it has been shown that decreased prostaglandinE2 synthesis halts gastrulation
143
. 
However, to date, how PGE2 regulates cell motility remains unclear. Speirs et al.
143
 
showed that PGE2-deficient zebrafish embryos, impaired in gastrulation movements, 
exhibit markedly increased cell-cell adhesion, which contributes to defective cell 
movements in the gastrula
143
. Similarly, in zebrafish embryos, loss of function of 
CELSR2 results in migration neuronal defects. Barbosa et al. showed that a C-
terminal truncated form of CELSR2 affects cell cohesion that primarily leads to the in 
vivo cell movement defects
116
. These data suggest that PGE2 could regulate cell 
migration by modulating CELSR2 function in cell-to-cell contacts and that PGE2 
binding to CELSR2 could require the receptor C-terminal tail to initiate a signalling 
pathway. One of the signalling pathways that PGE2 could modulate through CELSR2 
is PCP
120
. Indeed, phenotype of CELSR2 mutants is similar to that of FZD3 mutants, 
and other PCP proteins also implicated in cell migration
120
. 
The potential ability of PGE2 to allosterically modulate CELSR2 to regulate cell 
adhesion and cell migration, could have important implications also in pathological 
processes such as cancer metastasis
143
. Indeed, both CELSR2 and PGE2 expression 
levels have been proved to be associated to cancer cell invasiveness. This is also 
consistent with the identification of single amino acid substitutions (L2496I,  P2526Q 
and A2530V) in the PGE2 ligand binding site on CELSR2 that have been associated to 
the highly invasive tumors esophageal cancer, melanoma and urinary bladder cancer, 
respectively. 
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Moreover, also mutations of some amino acid residues involved in the ligand binding 
sites of cholesterol and retinoic acid have been associated to cancer. In the cholesterol 
binding site, the single amino acid substitutions R2413L and W2487C A2417T have 
been associated to liver cancer, stomach cancer and lung cancer, respectively . On the 
contrary, in the retinoic binding site, the single amino acid substitutions F2454V and 
M2533I have been associated to uterine and colorectal cancer, respectively. Our data 
suggest that, in some cases, loss of the GPCR allosteric modulation could be 
implicated in tumorigenesis. This is consistent with the current idea of using allosteric 
modulators as a new pharmacological strategy in the cancer therapy. Moreover, 
allosteric modulators as new GPCR-targeted drugs provide several mechanistic 
advantages, including the ability to distinguish between closely related receptor 
subtypes. Recently, the discovery of allosteric ligands that confer bias and modulate 
some, but not all, of a given receptor’s downstream signaling pathways can provide 
pharmacological modulation of cancer and other pathological conditions with 
remarkable precision
144
. 
None of the molecules till here identified as CELSR2 modulators, is predicted to target 
the orthosteric binding site of CELSR2. This could suggest that, even in the absence of 
the ECD, the CELSR2 TMD does not use its orthosteric binding site to allocate any 
molecule. This is in a way supported by the fact that while the ECD of CELSR2 is 
highly conserved among species, the TM bundle is less conserved.  
Finally, the allosteric modulators we identified derive from the apolar ethyl acetate 
fraction. Although less effective than the ethyl acetate fraction, also the aqueous 
fraction was active on rescuing CELSR2 mutant. This polar fraction represent  a new 
source of molecules that could target the orthosteric binding site of CELSR2. 
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MATERIALS AND METHODS 
Reagents. Salts and organic solvents are from Sigma Aldrich (USA) and Applichem 
(Germany), are handled according to manufacturer instructions. 
Cell culture. Hek293 cells and HuH7.5 cells  were cultured in DMEM (Dulbecco’s 
Modified Essential Medium) supplemented with 10% FBS (Fetal Bovine Serum), 
Glutamax and Pen/Strep antibiotics. Hek293 transfections were performed with 
polyethylenimine (PEI) according to the manufacturer’s protocol. On the contrary, 
Huh7.5 and U87MG transfections were performed with Lipofectamine 2000 according 
to manufacturer’s protocol. OrphG cell clones are obtained by transfecting cells with 
the corresponding cDNA cloned in pcDNA 3.1(Invitrogen). 
Mutagenesis. All of  the mutants of  CELSR2 were obtained by site-directed 
mutagenesis using CELSR2 cDNA (Origene) as a template. 
Antibodies Rabbit polyclonal anti-V5 ( Sigma-Aldrich) was used at 1:1000 dilution 
for immunofluorescence (IF) and 1:2000 dilution for western blot (WB); Mouse 
monoclonal anti-HA (HA-7, Sigma-Aldrich) was used at 1:2000 dilution for 
immunofluorescence (IF); Rabbit anti-CELSR2 abcam was used at 1:500 dilution for 
Western blot (WB); Other antibodies used:  rabbit polyclonal anti-HA (H6908, Sigma-
Aldrich; dilution of 1:200 for IF); Peroxidase-conjugated anti- rabbit IgG (A0545, 
Sigma-Aldrich WB 1:5,000); Texas Red–conjugated anti-rabbit IgG (111-025-003, 
Jackson ImmunoResearch Laboratories; 1:500 dilution for IF); Texas Red-conjugated 
anti-mouse (115-025-003, Jackson ImmunoResearch Laboratories) at 1:500 dilution 
for IF;  
Immunofluorescence. Cells were grown up on glass coverslips and then were fixed in 
3,7% formaldehyde/PBS pH 7.4 freshly made for 30 minutes at room temperature 
(RT). Formaldehyde was quenched by incubating the coverslips for 30 minutes in 0.1 
M glycine/PBS. Cells were permealized in 0.1% Triton/PBS pH 7.4 for 10 minutes at 
RT. Glass coverslips were then incubated with primary and secondary antibodies 
diluted in PBS for 1 h and 30 min at RT, respectively. After fixing coverslips with 
glycerol/PBS 1:1 on slides, cells were analyzed with a Leica TCS-SMD-SP5 confocal 
microscope. 
Western blotting. Samples were diluted in 20 mM Tris HCl (pH 6.8), 50 mM DTT, 
1% SDS, 5% glycerol and bromophenol blue and then incubated  for 20 min at 37° C. 
Samples were loaded on a SDS-PAGE gel. The run was performed at 100 V at 25° C. 
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After the run, proteins were transferred onto a nitrocellulose filter (Schleicher-Schuel) 
at 80 V for 1 h at 4° C. Filters were blocked in PBS supplemented with 3% nonfat dry 
milk (Bio-Rad) for 2 h at 25° C and incubated with primary and secondary antibody 
diluted in PBS supplemented with 0.3% nonfat dry milk in PBS. The ECL reaction 
was performed using the Lumi Light ECL Kit (Roche) according to the manufacturer’s 
procedures. 
Metabolite three phase extraction from Zebrafish eggs. More than 100.000 
zebrafish eggs were lysed and the solution was evaporated to dryness on a rotatory 
vacuum evaporator set at a maximum temperature of 40° C. This constituted the crude 
extract, which was dissolved in distilled water to be partitioned subsequently with n-
hexane, ethyl acetate and n-butanol to afford non-polar, semi-polar and polar fractions 
respectively. The extracts were weighed and stored at -20° C. The hexane (25 mg), 
ethyl acetate (7 mg),  butanol (26 mg) and residual aqueous fractions (242 mg) were 
dissolved in DMSO (10mg/ml) and further separated after centrifugation at 112 RCF 
in an insoluble and soluble fraction. 
Mass spectrometry analysis. Analyses were performed in direct infusion following a 
previous protocol [31] employing a Hamilton syringe (250 μl) at a flow rate of 2 
μL/min. Data were acquired on a SolariX XR 7T (Bruker Daltonics, Bremen, 
Germany). The instrument was tuned with a standard solution of sodium 
trifluoracetate. Mass Spectra were recorded in broadband mode in the range 100–1500 
m/z, with an ion accumulation of 20 ms, with 32 scans using 2 million data points 
(2M). Nebulizing (N2) and drying gases (air) were set at 1 and 4 ml/min, respectively, 
with a drying temperature of 200 °C. Both positive and negative ESI ionization were 
employed. Five replicates of each injection were carried out. The instrument was 
controlled by Bruker FTMS Control, MS spectra were elaborated with Compass Data 
Analysis version 4.2 (Bruker), identification of compounds based on accurate MS 
measurements was performed by Compound Crawler ver. 3.0 and Metaboscape 3.0 
(Bruker). Metabolites signals were normalized using internal standards. Comparisons 
and differences were analyzed for statistical significance by two-way Anova test and 
Bonferroni posttests analysis. All graphs, bars or lines indicate mean and error bars 
indicate standard error of the mean (s.e.m.). Furthermore, Partial Least Square 
Discriminant Analysis (PLS-DA) was used as classification model. All graphs, bars or 
lines indicate mean and error bars indicate standard error of the mean (s.e.m.). 
Statistical analysis was performed using Statistica software (StatSoft, Oklahoma, 
USA) and Minitab (Minitab Inc, Pennsylvania, USA). 
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SUPPLEMENTARY FIGURES 
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Supplementary Figure 1. Positive electrospray ionization (ESI) 
Fourier-transform ion cyclotron resonance  (FT-ICR) of the Ethyl 
acetate fraction. 
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Supplementary Figure  2. Expansion of the Positive electrospray 
ionization (ESI) Fourier-transform ion cyclotron resonance  (FT-
ICR) of the Ethyl acetate fraction. 
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Supplementary Figure  3. Negative electrospray ionization (ESI) 
Fourier-transform ion cyclotron resonance  (FT-ICR) of the Ethyl 
acetate fraction. 
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Supplementary Figure  4. Expansion of the negative electrospray 
ionization (ESI) Fourier-transform ion cyclotron resonance  (FT-
ICR) of the Ethyl acetate fraction. 
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